text:
User talk:Ghostal

Image copyright
Thanks for uploading images on Wikibooks. However, the images may soon be deleted unless we can determine the copyright holder and copyright status. The Wikimedia Foundation is very careful about the images included in Wikibooks because of copyright law (see Wikibooks' Copyright policy).

The copyright holder is usually the creator, the creator's employer, or the last person who was transferred ownership rights. Copyright information on images is signified using copyright templates. The three basic license types on Wikibooks are open content, public domain, and fair use. Find the appropriate template in Image copyright tags and place it on the image page like this:.

Please signify the copyright information on all images you have uploaded or will upload. Remember that images without this important information or giving false information can be deleted by an administrator. If you have any questions, ask them at the Staff lounge. Thank you.--Az1568(Talk) 07:11, 20 January 2007 (UTC)

Reorganisation?
Talk:Organic_Chemistry

A bit of constructive criticism to consider! Ewen 20:22, 30 January 2007 (UTC)

Copyright problem with Image:Williamsonsynthesis.gif
Thanks for uploading Image:Williamsonsynthesis.gif. The Wikimedia Foundation is very careful about what Wikibooks includes because of copyright law, and requires that we maintain a strict copyright policy. Image:Williamsonsynthesis.gif and other files you uploaded may soon be deleted unless we can determine the copyright holder and status. The copyright holder is usually the creator, the creator's employer, or the last person who was transferred ownership rights. Please take the time to read Media to learn more about what copyright information is required to satisfy our requirements and remember to include this important information for every file that you upload in the future as well. If you have any questions, feel free to contact me, or ask another Wikibookian at the help desk. Thank you.

See for a complete list of your uploads which may get deleted soon.

– Mike.lifeguard  | talk 00:43, 21 September 2007 (UTC)

title: User talk:Ghostal


text:
User:Stormie

See Wikipedia:User:Stormie

license: Creative Commons - Attribution Share-Alike - https://creativecommons.org/licenses/by-sa/4.0/

title: User:Stormie


text:
Electronics/RC transient

For a series RC consist of one resistor connected with one capacitor in a closed loop.

Circuit Impedance
In Polar Form Z/_θ
 * $$ Z = R \angle 0 + \frac{1}{\omega C} \angle - 90$$
 * $$ Z = |Z| \angle \theta = \sqrt{R^2 + (\frac{1}{\omega C})^2}\angle Tan^ -1 \frac{1}{\omega RC}$$

In Complex Form Z(jω)
 * $$Z = Z_R + Z_C = R + \frac{1}{j\omega C} = \frac{1}{j\omega C} (1 + j\omega RC)$$
 * T = RC

Differential Equation of circuit at equilibrium

 * $$C \frac{dV}{dt} + \frac{V}{R} = 0$$
 * $$\frac{dV}{dt} = - \frac{1}{RC} V$$
 * $$\frac{1}{V} dV = - \frac{1}{RC} dt$$
 * $$\int \frac{1}{V} dV = - \int \frac{1}{RC} dt$$
 * $$\ln V = - \frac{1}{RC}t + C$$
 * $$ V =  e^(\frac{-t}{RC} + C) = e^C \cdot e^\frac{-t}{RC}$$
 * $$ V = A e^{\left(\frac{-t}{RC}\right)} = A e^{\left(\frac{-t}{T}\right)}$$

Time Constant

 * T = R C

 * {| class="wikitable" width=50%

! t !! V(t) !! % Vo
 * 0 || A = eC = Vo || 100%
 * 1/RC|| .63 Vo || 60% Vo
 * 2/RC|| Vo ||
 * 3/RC || Vo ||
 * 4/RC|| Vo ||
 * 5/RC || .01 Vo || 10% Vo
 * }
 * 3/RC || Vo ||
 * 4/RC|| Vo ||
 * 5/RC || .01 Vo || 10% Vo
 * }
 * 5/RC || .01 Vo || 10% Vo
 * }
 * }

 * Capacitor_Charge-Discarge.svg

Angle Difference Between Voltage and Current
Current leads Voltage on an angle; Does this mean in measuring a angle of DC current causes a decrease in current? Let us take some time to understand the previous math in determing a factor of sinuous solution.
 * $$Tan\theta = \frac{1}{\omega RC} = \frac{1}{f} \frac{1}{2\pi RC} = t \frac{1}{2\pi RC}$$

Change the value of R and C will change the value of Angle Difference, Angular Frequency, Frequency and Time
 * $$\omega= \frac{1}{RC} \frac{1}{Tan\theta}$$
 * $$f = \frac{1}{2\pi} \frac{1}{RC} \frac{1}{Tan\theta}$$
 * $$t = 2\pi RC Tan\theta$$

u

Application

When the switch is open, the initial voltage across the capacitor is zero. When the switch closes (which we will refer to as time zero) the capacitor charges via the resistor to $$V_0$$.

When the switch is closed, the circuit must follow the relationship:
 * $$V_0=v_c(t)+i_c(t)R$$
 * $$V_0=v_c(t)+\frac{dv_c(t)}{dt}RC$$

which is derived by analysing the circuit using Kirchoff's Voltage Law.

By letting $$\tau=RC$$ and rearranging the equation:
 * $$\frac{dv_c(t)}{dt}+\frac{1}{\tau}v_c(t)=\frac{1}{\tau}V_0$$

This is a first order linear differential equation with integrating factor:
 * $$e^{\int \frac{1}{\tau}dt}$$
 * $$e^{\frac{t}{\tau}}$$

Multiplying both sides by the integrating factor:
 * $$\frac{dv_c(t)}{dt}e^{\frac{t}{\tau}}+\frac{1}{\tau}v_c(t)e^{\frac{t}{\tau}}=\frac{1}{\tau}V_0e^{\frac{t}{\tau}}$$

Note that:
 * $$\frac{d}{dt}[e^{t/\tau}v_c(t)]=\frac{dv_c(t)}{dt}e^{\frac{t}{\tau}}+\frac{1}{\tau}v_c(t)e^{\frac{t}{\tau}}$$

Substituting and integrating both sides:
 * $$e^{\frac{t}{\tau}}v_c(t)=V_0e^{\frac{t}{\tau}}+K$$

where K is the integration constant.

When t=0
 * $$v_c(0)=0$$

Therefore:
 * $$K=-V_0$$

When t>0 this gives:
 * $$e^{\frac{t}{\tau}}v_c(t)=V_0e^{\frac{t}{\tau}}-V_0$$
 * $$v_c(t)=V_0-V_0e^{-\frac{t}{\tau}}$$
 * $$v_c(t)=V_0(1-e^{-\frac{t}{\tau}})$$

when t<0:
 * $$v_c(t)=0$$

 * [[File:Rc_circuit_plot.png]]

title: Electronics/RC transient


text:
File:Rc circuit plot.png

plot of rc circuit response plotted in GNUPLOT

title: File:Rc circuit plot.png


text:
Cookbook:Basil

| Herbs and Spices

Basil is an herb, the green leaves of which are used extensively in a variety of cuisines.

Characteristics
Basil leaves are bright green or purple, with a rounded teardrop shape. Some varieties may have a domed leaf surface. In terms of flavor, many basil varieties are reminiscent of mint, anise/clove, and pepper, with some having highly specific flavor profiles akin to lemon or chocolate.

Varieties
There are multiple varieties of basil with different color and flavor profiles:

 * Sweet/Italian basil: variety of basil used in Western and Mediterranean cuisines; broad domed leaves.
 * Thai basil: narrower leaves with purple stems; tastes more like mint or anise than sweet basil does; used in Thai cuisine.
 * Holy basil (krapow): distinctive, hot flavor unlike sweet and Thai basil; used in Thai cooking.
 * Lemon basil: lemony flavor; used in Indonesian cooking, eaten raw as an accompaniment to fried fish or duck.
 * Opal basil:  purple leaves, strong flavor.

Seasonality
Summer is basil season. In September (northern hemisphere) the plant will flower, indicating the end of its season. Basil will not survive frost and thrives on sunlight, but many people manage to grow or keep basil inside during the winter months.

Selection and storage
Basil is best used fresh and can usually be bought either as a potted plant or harvested leaves. The leaves on the potted plant will remain fresh provided the plant itself is well cared for. Harvested leaves wilt when chilled, and they typically keep only for 1 or 2 days—they are best used on the day of purchase or frozen in oil. The leaves can then be used from frozen in recipes where appearance is not important. Overall, be delicate when handling fresh basil to prevent bruising.

Basil can also be bought dried and stored in a jar, which is best kept in a cool dark place. However, fresh basil is far preferable since it loses many of its distinctive flavor characteristics when dried.

Use
Basil is widely used in Mediterranean and Southeast Asian cuisines, where it can be incorporated into condiments, salads, curries, and beverages. Sweet basil takes center stage in basic pesto, and it is often paired with tomato. Because of their pleasing appearance, the leaves are often used as a garnish. Basil seeds may be used in beverages or desserts, where they take on properties similar to those of chia seeds.

Processing
Chopping basil is an inefficient way to release the flavors from its cellular structure. To maximize flavor from chopped basil, first place it in a ziplock bag, and then pound it with the flat of cleaver or a meat tenderizer. Pound until the leaves appear wet, and then proceed to chopping.

The flavor compounds in basil will dissipate with prolonged cooking, so add it nearer to the end of cooking, and only cook it as much as is necessary to flavor the dish.

title: Cookbook:Basil


text:
Template talk:Information technology bookshelf

Embedded systems programming


text:
User:JonTheNiceGuy

This is a test. I've never done any wiki before...

title: User:JonTheNiceGuy


text:
User talk:JonTheNiceGuy

Hi, Jon, and welcome to Wikibooks! I see you experimented with your user page, and I'd like to thank you for that, many first time editors choose to add that type of test message to a module. If you'd like to do more experimenting, feel free to edit the Sandbox, you can also see what other users have been able to do there. If you have any questions, feel free to ask at the Staff lounge, or you can ask me at my talk page. Again, welcome, and have fun. Gentgeen 13:33, 9 Oct 2004 (UTC)

PS: If you'd like to sign a talk page (like I did above), add four tildies ( ~ ), which automaticly becomes a link to your user page and a time stamp. 3 tildies makes just the link. Gentgeen

title: User talk:JonTheNiceGuy


text:
Cookbook:Garnish

A garnish is a small, usually raw, addition to a cooked meal, intended to give visual appeal and perhaps a contrast in flavour and texture. The classic, indeed hackneyed, garnish is a sprig of parsley on top of just about anything, but garnishes can include croûtons in soup, or a slice of lemon on fish.

title: Cookbook:Garnish


text:
User:Snowspinner

I am also Snowspinner on the English Wikipedia.

title: User:Snowspinner


text:
Cookbook:Dal

Dal is an Indian term referring to split, often skinless pulses. There are many varieties.

Characteristics
The exact characteristics of dal will depend on the specific pulse it comes from. In general, because dal is split and skinless, it cooks much more quickly than the whole pulse.

Varieties
The following are various dals commonly sold:
 * Chana dal: split brown chickpeas; golden yellow in color
 * Chowli dal: split black eyed peas; cream/tan in color
 * Masoor dal: split red lentils; bright orange in color
 * Moong dal: split mung beans; bright yellow in color
 * Toor dal: split pigeon peas; golden yellow in color
 * Val dal: lablab beans; cream/tan in color
 * Urad dal: urad/black gram beans; cream/tan in color

Selection and storage
Store dal in an airtight container at room temperature, away from any moisture. It lasts for a long time, though the cooking time increases the older the dal gets.

Use
Typically dal is boiled to a porridge consistency, then spiced by adding vegetable oil or ghee in which spices such as cumin and coriander seeds have been fried. Dal can also be fermented and ground to make dosa or idlis, or used in some desserts. And, it can even be used as a garnish, as in

To make simple cooked dal, combine the dal with 3–4 times the water, then simmer until tender. You'll want to check them periodically to assess their doneness and make sure they don't dry out before they're cooked.

title: Cookbook:Dal


text:
Cookbook:Raita

| Indian cuisine

Raita is an Indian garnish often served with spiced dishes. It acts as a cooling flavour as the fat in the yogurt dissolves and mollifies chili in the curry, while the taste of cucumber and fresh mint or other herbs refreshes the palate.

The essential ingredient is yogurt.

Ingredients

 * ⅛ cup grated cucumber (about 1 inch of cucumber)
 * ½ cup plain yogurt
 * 2–3 mint leaves, chopped
 * 2 cilantro leaves, chopped
 * 1–2 tbsp finely chopped or minced onions (optional)
 * Salt (coarse salt preferred)
 * Chile powder
 * Ground cumin

Procedure

 * 1) Squeeze the grated cucumber to remove and discard excess liquid.
 * 2) Stir the cucumber into the yogurt.
 * 3) Add chopped mint, cilantro, and onion.
 * 4) Add salt to taste.
 * 5) Sprinkle a little ground cumin on top.
 * 6) Sprinkle with chili powder if desired.
 * 7) Refrigerate and serve cold.

title: Cookbook:Raita


text:
File:Mesh1.png

example of mesh analysis

title: File:Mesh1.png


text:
Physics Study Guide/Physics constants

= Commonly Used Physical Constants =

To Be Merged Into Table
This list is prepared in the format
 * Constant (symbol) : value

 * Coulomb's Law Constant (k) : 1/(4 π ε0) = 9.0 × 109 N·m2/C2
 * Faraday constant (F)          : 96,485 C·mol−1
 * Mass of a neutron (mn) : 1.67495 × 10−27 kg
 * Mass of Earth : 5.98 × 1024 kg
 * Mass of the Moon : 7.35 × 1022 kg
 * Mean radius of Earth : 6.37 × 106 m
 * Mean radius of the Moon : 1.74 × 106 m
 * Dirac's Constant ($$\hbar$$) : $$h/(2\pi)$$ = 1.05457148 × 10−34 J·s
 * Speed of sound in air at STP : 3.31 × 102 m/s
 * Unified Atomic Mass Unit (u) : 1.66 × 10−27 kg

=See Also=

Wiki-links

 * Wikipedia Article

title: Physics Study Guide/Physics constants


text:
Radiation Oncology/RTOG Trials

Overview of RTOG Trials

RTOG Website Links
Please visit The RTOG Website for the latest trials and protocol information.
 * RTOG dose constraints
 * List of RTOG published trials
 * List of RTOG abstracts (ASTRO and ASCO)
 * RTOG scientific sessions
 * RTOG newsletter
 * RTOG meeting minutes - divided by site committee
 * PMID 11702729 (2001) - "RTOG Publications since 1996" — IJROBP Vol 51 No 3 Suppl 2, 125-145, 2001.
 * "RTOG manuscripts and abstracts submitted for publication: As of May 2001" — IJROBP Vol 51 No 3 Suppl 2, 146-8, 2001.

 * Finding RTOG trial results
 * From NCI Website:
 * Search for RTOG Trial (change the number for the trial you're searching for) - provides list of publications
 * Advanced Search - For any clinical trial. Be sure to set status of trial as active/closed; useful parameters include cooperative group, protocol id, and type of cancer.
 * Searching Pubmed for a specific RTOG trial - Search - (change the number to the trial you're searching for)

Pages by organ site

 * RTOG Anal Trials
 * RTOG Bladder Trials
 * RTOG Brain Trials
 * RTOG Cervix Trials
 * RTOG Esophageal Trials
 * RTOG Pancreas Trials
 * RTOG Prostate Trials
 * RTOG NSCLC Trials
 * RTOG SCLC Trials
 * RTOG Liver Trials
 * RTOG Melanoma Trials
 * RTOG Sarcoma Trials

See also:
 * PMID 7558966 (1995) — "Evolution and accomplishments of the Radiation Therapy Oncology Group." Cox JD et al. Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):747-54.
 * PMID 7635796 (1995) — "The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer." Byhardt RW et al. Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1513-25.
 * PMID 8655364 (1996) — Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer." Fu KK et al. Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):425-38.

10-XX and later

 * 10-14 Protocol (PDF) (ongoing) - Breast - Phase II. Repeat breast preserving surgery and 3D-CRT PBI for local recurrence
 * 10-16 Protocol (PDF) - Oropharynx - Phase III. Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

00-XX to 09-XX

 * 09-37 Protocol (PDF) (ongoing) - SCLC - Extensive stage. Phase III. PCI vs PCI + consolidative extra-cranial RT

 * 09-26 Protocol (PDF) (ongoing) - Bladder - Phase II. T1. Selective bladder preservation
 * chapter link

 * 09-21 Protocol (PDF) (ongoing) - Endometrium - Phase II. IMRT + concurrent cisplatin/bevacizumab + adjuvant carboplatin/paclitaxel

 * 09-20 (ongoing) - H&N - A phase III randomized trial of surgery followed by radiotherapy (IMRT) +/- cetuximab for intermediate risk HN SCCA

 * 09-15 Protocol (PDF) (ongoing) - NSCLC - Phase II randomized. SBRT inoperable central lesions 34/1 vs. 48/4

 * 08-15 Protocol (PDF) (ongoing) - Prostate - Phase III randomized. Dose escalated RT ± 6 month ADT

 * 08-13 Protocol (PDF) (ongoing) - NSCLC - Phase I/II. SBRT inoperable peripheral lesions 50/5 -> 60/5

 * 07-24 Protocol (PDF) (ongoing) - Cervix - High risk, early stage pts after Rad Hyst. Adjuvant Chemo/RT +/- adjuvant chemo.

 * 07-12 Protocol (PDF) (ongoing) - Bladder - Phase II randomized. Selective bladder preservation RT + 5FU/cisplatin vs RT + gemcitabine
 * chapter link

 * 06-30 Protocol (PDF) (ongoing - Sarcoma - Phase II. Preop IGRT in the extremity

 * 06-23 Protocol (PDF) - SCLC - Phase II. AHFX 61.2/34 Gy with concurrent cisplatin/etoposide and growth factor support
 * chapter link

 * 06-18 Protocol (PDF) (ongoing) - NSCLC - Phase II. SBRT in operable patients. 60/3

 * 06-17 Protocol (PDF) (ongoing) - NSCLC - Phase III. Standard (60 Gy) vs. High Dose (74 Gy) concurrent with carbo/taxol +/- Cetuximab in Stage IIIA/IIIB

 * 05-38 Protocol Summary (ongoing) - SCLC - Phase III, 3 arms. 45/30 BID vs 70/35 QD vs AHFX 61.2/34. Concurrent cisplatin/etoposide
 * chapter link

 * 05-29 - Anal - Phase II. Dose-painted IMRT
 * chapter link

 * 05-24 (ongoing) - Bladder - A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer.
 * chapter link

 * 05-22 Protocol (PDF) (2005-2009) - H&N - A phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (C225) followed by surgery for residual disease for stage III and IV head and neck carcinomas.
 * 2011: ASCO Abstract 5500

 * 05-21 (ongoing) - Prostate - A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs AS and 3DCRT/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer

 * 05-15 - NSCLC - Comparative study of GTV definition +/- PET scan

 * 04-38 (ongoing) - Liver - Phase I. Dose escalation. 35 Gy in 3.5 Gy/fx -> 50 Gy in 5.0 Gy/fx in patients with metastatic liver cancer.

 * 04-36 Protocol (PDF) (ongoing) -- Esophagus -- Phase III. Non-surgical approach. Paclitaxel + Cisplatin + RT +/- Cetuximab
 * chapter link

 * 04-24 (ongoing) - Glioma - Phase II. High risk LGG (at least 3 risk factors: age >=40, tumor diameter >=6cm, tumor crossing midline, astrocytoma subtype, pre-op neurologic deficit). RT + Temozolomide. Comparison will be to historical EORTC patient population

 * 04-21 (Closed) - Head & Neck - Phase III. Locally recurrent, previously irradiated H&N: Concurrent Re-RT/Chemo vs. Chemo alone
 * Closed due to poor accrual

 * 04-18 Protocol (PDF) (Closed) - Cervix/Endometrial - Phase II. Post-op IMRT.

 * 04-17 Protocol (PDF) (Closed) - Cervix - Phase II. Locally advanced. Definitive RT + cisplatin + bevacizumab.

 * 04-15 (2006-2009) - Prostate - Phase III. Low risk, T1-T2, PSA < 10, G 2-6. Randomized to 73.8 Gy in 41 fractions (1.8 Gy/fx) vs 70 Gy in 28 fractions (at 2.5 Gy/fx).

 * 04-13 / NSABP B-39 (ongoing) Protocol -- "A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer"

 * 04-12 / SWOG S0332 Protocol - NSCLC - NSCLC Stage IIIA (N2) surgically resectable. Induction chemo vs chemo/RT followed by surgery then chemo.
 * Closed due to poor accrual

 * 04-11 (2005-6) - Pancreas - Phase II. RT + bevacizumab + capecitabine, with maintenance gemcitabine and bevacizumab
 * PMID 19636002 (2009)

 * 03-30 Protocol - Sarcoma - Phase II. Preop thalidomide and RT or doxorubicin/ifosfamide/dacarbazine and RT

 * 03-24 Protocol - NSCLC - Phase II. Chemo-RT + Cetuximab in Stage IIIA/IIIB
 * Chapter link
 * PMID 21555682 (2011)

 * 03-21 - Prostate - Intermediate localized PCA. 45 Gy EBRT (no IMRT) + 19 Gy (2 fractions) HDR boost
 * PMID 20207506 (2010): Acceptable toxicity

 * 03-19 Protocol (PDF) - Breast - Phase I/II. 3D-CRT confined to lumpectomy cavity for Stage I and II
 * chapter link
 * PMID 19910132 (2009): Initial efficacy and toxicity comparable

 * 03-15 Protocol (PDF) - Supportive Care - Phase III. Octreotide for diarrhea prevention in anal and rectal cancer
 * chapter link
 * PMID 20339140 (2010): No benefit

 * 02-46 - Esophagus - Phase II. Paclitaxel Based Chemoradiation Regimen With Selective Surgical Salvage for Resectable Locoregionally Advanced Esophageal Cancer
 * chapter link
 * ASTRO Abstract: Feasible

 * 02-41 - SCLC - Phase I. Irinotectan + cisplatin + RT (45/30 BID or 70/35 QD in limited stage SCLC

 * 02-39 (ongoing) Protocol (PDF) - SCLC' - Phase II. Accelerated high dose RT (61.2 Gy in 5 weeks) with concurrent cisplatin/etoposide in limited small cell lung cancer

 * 02-36 Protocol (PDF) - NSCLC - Phase II. SBRT inoperable patients 60/3

 * 02-35 Protocol link - NSCLC - PET for pre- and post- treatment assessment in locally advanced NSCLC

 * 02-34 (ongoing) - H&N - Post-op. A phase II randomized trial of surgery followed by chemoradiotherapy plus C225 (cetuximab) for advanced squamous cell carcinoma of the head and neck.
 * ASTRO Abstract 2007: RT + cisplatin or docetaxol + cetuximab is safe and feasible

 * 02-33 - Bladder - TURBT followed by induction chemo/RT (BID RT and randomized to Taxol + cisplatin vs 5-FU and cisplatin), evaluate tumor response, then consolidation chemo/RT (BID RT and randomized to same arm as above), then 4 cycles adjuvant chemo (Gemzar, Taxol, Cisplatin). Cystectomy for those who fail induction.
 * chapter link

 * 02-32 (ongoing) - Prostate - Intermediate localized PCA. EBRT + PB vs. PB alone

 * 02-29 Protocol (PDF) (ongoing) - NSCLC - Phase II. IIIA-B, resectable. Preop chemo/RT -> surgery -> additional chemo.

 * 02-25 (2003-2005) Protocol - H&N - Phase II. IMRT use in Nasopharynx
 * chapter link
 * PMID 19564532 (2009): IMRT feasible in multi-institutional setting

 * 02-15 (ongoing) - Prostate - Treatment of ED. Sildenafil x 12 weeks crossover study.

 * 02-14 Protocol (PDF) - NSCLC - PCI vs observation in locally advanced NSCLC

 * 02-13 Protocol (PDF) - NSCLC - Phase I/II. Celebrex with RT in locally advanced NSCLC
 * Closed - poor accrual

 * 02-12 / Intergroup PCI99-01 (1999-2005) Protocol (PDF) - SCLC - PCI with Limited Disease SCLC - Intergroup study. PCI 25 Gy (at 2.5 Gy/fx) vs. 36 Gy (at 2/fx) vs. 36 Gy (at 1.5 BID).
 * chapter link
 * PMID 19386548: No difference in brain mets, worse survival with higher dose

 * 02-11 (2002-2004) GBM - CNS - RT with concurrent/adjuvant gefitinib
 * PMID 23182702: Well tolerated but no benefit over historical controls

 * 01-32 Protocol - Sarcoma - Phase II. GIST. Neoadjuvant and adjuvant Gleevec

 * 01-29 (2002-2005) Protocol (PDF) - H&N - Chemo/RT with conventional RT (70 Gy in 7 weeks) vs chemo/RT with concomitant boost (72 Gy in 6 weeks). Cisplatin (100 mg/m2) on days 1, 22, 43 (conventional) or 1 and 22 (C.B.). Enrolled selected Stage III-IV (T2N2-3M0, T3-4 Any N M0, no T1-2N1 or T1N2-3)
 * chapter link
 * ASTRO 2007: Comparable acute toxicity

 * 01-28 (closed March 2004) Protocol (PDF) - Cervix - Phase I/II. Celecoxib + chemo/RT (cisplatin + 5-FU) for locally advanced cervical cancer, stage IIB-IVA or node-positive IB-IIA.
 * PMID 17482376 (2007), PMID 17084549 (2007), PMID 18299147 (2008), PMID 19509178 (2009)

 * 01-26 (ongoing) - Prostate - High dose 3D-CRT/IMRT randomized to 70.2 Gy vs. 79.2 Gy

 * 01-18 (closed) - Brain Mets - Phase III. WBRT 37.5/15 +/- Thalidomide
 * See chapter for more details
 * PMID 18164847, 2007 - No benefit

 * 01-17 (closed) - NSCLC - Phase I/II. Dose escalation, 3D-CRT + concurrent carboplatin/paclitaxel
 * chapter link
 * PMID 20368547 (2010), PMID 20457350 (2010)

 * 01-16 Protocol (PDF) (2001-2007) - Cervix - Phase I/II. Positive Para-Aortic LN (or high common iliac). Extended field RT +/- Amifostine.
 * PMID 17398031 (2007)

 * 01-14 (closed)(Protocol) - Gastric - Phase II. Randomized comparison of 2 chemo-RT regimens (Induction 5-FU/cisplatin/taxol + concurrent 5-FU/taxol + RT vs. induction cisplatin/taxol + concurrent cisplatin/taxol)
 * chapter link
 * ASTRO 2006 abstract: 5-FU arm too toxic
 * PMID 19273696 (2009)

 * 01-13 (closed) - Esophagus - Phase III. Compares two induction + concurrent chemo/RT regimens)
 * chapter link
 * PMID 18574157 (2008): Both arms too toxic

 * 00-24 (2001-3) - H&N - post-operative chemo/RT. Early Taxol (within post-op day 7-14) then RT to 60 Gy with cisplatin/taxol weekly for the last 3 weeks
 * PMID 19720915 (2009)

 * 00-22 (2001-2005) Protocol (PDF) - H&N - Phase I/II study of conformal and intensity modulated irradiation for oropharyngeal cancer. Stage T1-2, N0-1.
 * chapter link
 * PMID 19540060 (2009): IMRT feasible

 * 00-20 (Closed) - Pancreas - Phase II, weekly gemcitabine + paclitaxel + XRT followed by farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer

 * 00-19 (closed) - Prostate - Intermediate localized PCA. Phase II EBRT + PB

 * 00-17 Protocol (PDF) - NSCLC - Phase I. GEM/paclitaxel vs. GEM/carboplatin and RT for Stage IIIA/B NSCLC
 * PMID 19096311 (2009)

 * 00-15 SWOG S9900 Protocol - NSCLC - Phase III. Surgery vs Neoadjuvant paclitaxel/carboplatin for Stage IB, II, and selected IIIA patients
 * PMID 20231678

 * 00-12 (2001-2003) - Rectum (Protocol (PDF)) - Randomized Phase II. Preoperative chemo/RT.
 * PMID 16446336, 2006 — "Randomized Phase II Study of Neoadjuvant Combined-Modality Chemoradiation for Distal Rectal Cancer: Radiation Therapy Oncology Group Trial 0012." Mohiuddin M et al. J Clin Oncol, Vol 24, No 4 (February 1), 2006: pp. 650-655.

 * 00-11 (closed) - Prostate - Unfavorable pT3 PCA s/p RP. AST x 2 years alone vs. EBRT + AST x 2 years vs. EBRT alone. Study closed due to non-accrual.

90-XX to 99-XX

 * 99-15 (Closed; pending) (Intergroup/SWOG 9927) - Breast - post-mastectomy RT for Stage II with 1-3 positive LN (T1-2N1)

 * 99-14 (2000-2000) Protocol - H&N - "A phase II trial of concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas."
 * PMID 15860857 (2005): Concomitant boost + concurrent cisplatin is feasible
 * PMID 18640496 (2008): long term results

 * 99-13 (2000-2) Protocol - H&N, Skin Toxicity - "A phase III comparison of Biafine to declared institutional preference for radiation induced skin toxicity in patients undergoing radiation therapy fro advanced squamous cell carcinomas of the head and neck."
 * PMID 16648511 (2006)

 * 99-11 (2000-2003) Protocol (PDF) - H&N - "Phase II Study of Paciltaxel and Cisplatin in Combination with split course concomitant hyperfractionated re-irradiation in patients with recurrent squamous cell cancer of the head and neck."
 * Chapter. PMID 17947728: High incidence of Grade 5 toxicity, but better OS than chemo alone

 * 99-10 (1999-2004) - Prostate - Intermediate risk PCA. AST/2 followed by EBRT/AST vs. AST/7 followed by EBRT/AST.

 * 99-09 (Closed) Protocol - ''NSCLC - Phase II. Resected Stage II-IIIA, adjuvant RT + vaccine immunotherapy (CeaVac and TriAb)

 * 99-06 (1999-2002) Protocol (PDF) - Bladder - "Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy
 * chapter link
 * PMID 19100600 (2009): Favorable tumor response

 * 99-05 (1999-2003) - Endometrium - A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Paclitaxel Chemotherapy following TAH/BSO for Patients with Endometrial Cancer. Grade 2-3 and Stage IC, IIA (with >50% myometrial invasion), or IIB.
 * chapter link
 * Closed due to poor accrual

 * 99-04 (1999-2004) Protocol (PDF) - Gastric - Phase II. Pre-op chemo and chemo-RT
 * PMID 16921048 (2006)

 * 99-03 (2000-2003) Protocol (PDF) - H&N - RT vs RT + weekly erythropoietin for pts with H&N cancer and anemia
 * chapter link. Closed early due to other published data suggesting a decrease in locoregional control in pts receiving erythropoietin.
 * PMID 17716826 (2007): No difference in outcomes

 * 99-02 (closed early, Oct 2004) - Prostate - High risk, localized PCA. (AST/2 + EBRT) +/- TEE (Paclitaxel, Estramustine, and Etoposide). Study closed due to increased thromboembolic toxicity due to Emcyt.
 * PMID 18990504 (2009)

 * 99-01 (2000-2) - H&N - Phase III, +/- GM-CSF for mucositis during RT.
 * PMID 17293228 (2007)

 * 98-12 (Closed) - Pancreas - Phase II, weekly Taxol + XRT for unresectable pancreatic cancer
 * PMID 14758134 (2004)

 * 98-11 (1998-2005) Protocol (PDF)- Anal - Induction/concurrent chemo/XRT with 5-FU/CDDP vs concurrent chemo/XRT with 5-FU/Mitomycin-C
 * chapter link
 * PMID 18430910 (2008)

 * 98-05 (1998-2000) - Prostate - Phase II, brachytherapy, low risk
 * PMID 17084551 (2007)

 * 98-04 (1999-2006) - Breast Surgery +/- RT for low or intermediate grade DCIS
 * chapter link
 * Closed due to non-accrual

 * 98-03 - CNS / GBM - Dose escalation.
 * PMID 18723297 (2009): Feasible

 * 98-02 (1998-2002) - CNS glioma - A Phase II Study of Observation in Favorable Low-Grade Glioma and A Phase III Study of Radiation with or without PCV Chemotherapy in Unfavorable Low-Grade Glioma.
 * Summary (PDF)
 * PMID 18976072 (2008, Low Risk Group)

 * 98-01 (closed) - Lung NSCLC - +/- Amifostine with hyperfractionated RT with concurrent chemo
 * chapter link
 * PMID 15800308 (2005): No benefit, PMID 18501528 (2008), PMID 19858383 (2009)

 * 97-16 (CALGB 9781) - Esophagus - Trimodality (cisplatin, 5-FU, XRT, surgery) vs surgery alone.
 * Chapter link. Closed early due to nonaccrual
 * 2006 ASCO Abstract: Survival advantage for trimodality therapy

 * 97-14 (closed) - Prostate, Breast, Palliation - Mets to bone. 3 Gy x 10 vs. 8Gy x 1
 * Conclusion ASTRO 2003 Abstract : "Palliative external beam radiation therapy is very effective in providing pain relief, with complete or partial improvement in pain seen in 66% of patients. Pain and narcotic relief is equivalent for both 30 Gy in 10 fractions and 8 Gy in a single fraction. At 3 months follow-up, there is no difference between the two treatment arms, regardless of stratification. Treatment was well tolerated with few adverse effects."

 * 97-13 - Breast, Skin Toxicity - Randomized phase III study comparing Best Supportive Care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation.
 * chapter link
 * PMID 11121627 (2000): No difference

 * 97-12 (1998-2002) - SCLC - Phase I. Dose escalation AHRT with concurrent cisplatin/etoposide.
 * chapter link
 * PMID 15890573 (2005): MTD 61.2 Gy

 * 97-08 (1997-1999) - Endometrium - Phase II. Post-operative chemo+RT for "high risk" (Stage IC-III). EBRT + concurrent cisplatin, BT followed by cisplatin + taxol x 4 cycles.
 * PMID 16545437 (2006), PMID 15093913 (2004)

 * 97-06 (1998-2000) - Bladder - Phase I/II trial. Operable muscle-invading. TURBT followed by cisplatin + BID RT followed by either selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
 * chapter link
 * PMID 14529770 (2003)

 * 97-05 - Lung - Phase II. Surgery + paclitaxel/carboplatin + concurrent RT
 * chapter link
 * PMID 15908657 (2005) - Good OS

 * 97-04 / Intergroup (1998-2002) - Pancreas - pre and post chemoradiation with 5-FU vs Gemcitabine for adjuvant treatment of resected pancreatic cancer
 * PMID 18319412
 * ASCO 2006 Abstract (Regine et al) - http://meeting.jco.org/cgi/content/abstract/24/18_suppl/4007

 * 97-03 (Closed 1999) - Head & Neck - Phase II. Advanced Stage III-IV. Randomized to 1) 70 Gy / 7 weeks with daily cisplatin and 5-FU during the last 10 days of RT; 2) 70 Gy / 13 weeks every other week with concurrent daily hydroxyurea and 5-FU ; 3) 70 Gy / 7 weeks with weekly cisplatin and paclitaxel.
 * PMID 15254053, 2004 (Preliminary results)
 * Abstract (Long term results, 2007)

 * 97-02 (Intergroup, CALGB 9343) - Breast - lumpectomy + tamoxifen +/- RT for women > 70
 * PMID 15342805

 * 97-01 Protocol (PDF) - NSCLC - Phase III. Randomized chemo/RT vs RT alone for Stage IIIA-IIIB.
 * Closed for poor accrual in 1999

 * 96-16 (CALGB 9633) - NSCLC - Phase III. Resected T2N0 lung +/- adjuvant chemotherapy
 * PMID 18809614 (2008)

 * 96-12 Protocol (PDF) - Vulva - Phase II, chemoradiation (5-FU + Mitomycin). Locally advanced (not treatable by radical vulvectomy).
 * Closed - poor accrual

 * 96-10 - H&N - Phase II. Reirradiation + chemotherapy in unresectable recurrent H&N
 * chapter link
 * PMID 17764087 (2008): Feasible approach, acceptable acute and late effects

 * 96-09 Protocol (PDF) - SCLC - Phase II. "Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer
 * PMID 15939930 (2005)

 * 96-08 (closed) - Prostate - Pathologically LN+. Indefinite AST +/- 70.2 Gy EBRT

 * 96-01 (closed) - Prostate - Post-op RT +/- Casodex 150 mg x 2 years for pT3 with PSA elevation.

 * 95-17 (1997-2000) - Breast - Phase I-II. Brachytherapy, LDR or HDR.
 * Toxicity: PMID 16503383 (2006)

 * 95-14 (1997-2000) Protocol (PDF) - Sarcoma - Preoperative RT - MAID - RT.
 * chapter link
 * PMID 16446334 (2006): Activity, but too toxic

 * 95-11 Protocol (PDF) (CALGB 9334) - Sclerosis of pleural effusion by talc thoracoscopy vs talc slurry
 * PMID 15764775 (2004): Similar in efficacy

 * 95-08 - CNS - 1-3 brain mets, randomized WBRT +/- radiosurgery - survival advantage for 1 met.
 * PMID 15158627 (2004) Full text

 * 95-07 - CNS - GBM. Phase I. RT + Topotecan.
 * PMID 11181676 (2001)

 * 95-06 (1995-1997) - Bladder - Phase I/II. BID chemo/RT after TURBT. Cisplatin + 5-FU.
 * chapter link
 * PMID 11110598 (2000)

 * 95-05 - H&N - Basic science. Evaluation of NPC patients for tumor angiogenesis by microvessel density
 * PMID 15708253 (2005): No difference in survival based on MVD <60 vs MVD >=60

 * 95-01 - H&N - Protocol (PDF) - Post-op. RT +/- chemo for high risk.

 * 94-17 (1995-97) - CNS - GBM. Phase II. RT 60 Gy + tirapazamine (3x/week x 12). Two dose levels.
 * PMID 10715295 (2002)

 * 94-15 / INT 0146 / NCCTG 93-46-53 (1994-2001) - Colon - Laparoscopic colectomy vs open colectomy.

 * 94-13 (1995-99) - Prostate - High risk (>15%) of LN+. Neoadjuvant/concurrent vs adjuvant hormones; and whole-pelvic vs prostate only RT.
 * PMID 12743142 (2003)

 * 94-10 - Lung - NSCLC medically inoperable or unresectable, Stage II-IIIB. Randomized to sequential chemo/RT vs one of two concurent chemo/RT arms (std or hyperfractionated).

 * 94-09 ECOG E4592 - NSCLC - Ancillary study to RTOG 91-05 / ECOG E3590 / INT 0115. Laboratory / Clinical correlative studies.

 * 94-08 (closed) - Prostate - Intermediate risk localized PCA. AST/2 followed by EBRT vs. EBRT alone.

 * 94-06 (closed) - Prostate - Phase I, 3D-CRT dose escalation, 68.4 - 79.2Gy.
 * Conclusion level V (78 Gy in 2 Gy/fx) ASTRO Abstract : "The rate of grade 3+ toxicity from 3DCRT with 78 Gy in 2.0 Gy fractions remains better than expected compared to historical controls. However, low-grade late toxicity is significantly higher in dose level V than dose level III. These differences may be dose and/or volume related."
 * Conclusion level IV (74 Gy in 2 Gy/fx) PMID 14967428 : "Tolerance to three-dimensional conformal radiotherapy with 74 Gy in 2-Gy fractions remains better than expected compared with historical controls. The magnitude of any effect from fraction size requires additional follow-up."

 * 94-05 - Esophagus - high (64.8 Gy) versus standard (50.4 Gy) dose
 * Chapter link
 * No difference in survival or loco-regional control

 * 94-04 - Lung - RT 60/30 +/- interferon beta
 * PMID 11955727 - Conclusion : "This multicenter, controlled Phase III trial failed to confirm the efficacy of Betaseron in patients receiving definitive radiotherapy for locally advanced, nonmetastatic non-small-cell lung cancer. The use of beta-interferon led to greater rates of both acute and late treatment-related toxicity."

 * 94-03 / INT 0144 / SWOG 9304 (1994-2000) Protocol - Rectum - Phase III. Post-op chemo/RT. 3-arm:
 * 1) bolus 5-FU -> RT + PVI 5-FU -> bolus 5-FU
 * 2) PVI 5-FU -> RT + PVI 5-FU -> PVI 5-FU
 * 3) bolus 5-FU + leucovorin + levamisole -> RT + bolus 5-FU + LV -> bolus 5-FU + LV + Lev

 * 94-02 / INT 0149 (1994-2002) - CNS, pure and mixed anaplastic oligodendroglioma. RT +/- neoadj PCV.
 * PMID 16782910 (2006)

 * 94-01 / INT 0147 - Rectum - preoperative vs postoperative chemo/RT
 * Closed due to poor accrual

 * 93-12 (1994-1996) - SCLC - Phase II. LS-SCLC, AHFX 45/30 BID with concurrent cisplatin/ifosfamide
 * chapter link
 * PMID 10944132 (2000): As effective as cisplatin/etoposide, but more toxicity

 * 93-11 - NSCLC - Dose escalation for NSCLC
 * chapter link
 * PMID 15667949 (2005): MTD 83.3 Gy (V20 <25%) or 77.4 Gy (V20 26-35%)

 * 93-10 (1994-1997) - CNS Lymphoma - Phase II, chemo->RT
 * chapter link PMID 12488408, 2002 - HD-MTX based regimen combined with consolidative RT is superior to RT alone when the overall survival data are compared to historical data. However, patients over age 60 had significant risk of late toxicity from the combined treatment.

 * 93-09 (Intergroup 0139) - Lung - Randomized Trial of Chemoradiotherapy to 61 Gy [no S] versus Chemoradiotherapy to 45 Gy followed by Surgery [S] Using Cisplatin Etoposide in Stage IIIa Non-small Cell Lung Cancer (NSCLC): Intergroup Trial 0139, RTOG (9309)
 * chapter link
 * Abstract ASTRO 2003 Video Presentation — Turrisi et al.
 * PMID 19632716 (2009)

 * 93-05 - CNS - Malignant gliomas, EBRT with BCNU +/- radiosurgery - no change in survival.
 * PMID 15465203 — "Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol." Souhami et al. Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60.

 * 93-02 - Melanoma - post-op H&N melanoma, 30 Gy/5 fx (twice/week) vs observation.
 * Closed due to poor accrual (20 pts enrolled).

 * 92-10 - Cervix - positive para-aortic LNs. HFx RT + concurrent 5-FU / cisplatin.
 * PMID 11704321 (2001)

 * 92-08 - Anal - RT dose escalation, split course
 * PMID 18472363 (2008): Split-course worse outcomes compared with historical controls

 * 92-07 - Esophagus - brachytherapy boost
 * Swallowing function: PMID 11693897 — "Swallowing function and weight change observed in a phase I/II study of external-beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 9207)." Gaspar et al. Cancer J.  2001 Sep-Oct;7(5):388-94.
 * Final report: PMID 10699886 Full Text — "A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report." Gaspar et al.  Cancer. 2000 Mar 1;88(5):988-95.
 * Preliminary report: PMID 9112458 Full Text — "A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report." Gaspar et al.  Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):593-9.

 * 92-05 - Lung - accelerated hyperfractionation
 * PMID 10776986 — "Accelerated hyperfractionation for bronchogenic cancer: Radiation Therapy Oncology Group 9205." Herskovic et al. Am J Clin Oncol. 2000 Apr;23(2):207-12.

 * 92-04 - Lung - Phase II, randomized induction chemo + concurrent chemo/RT vs concurrent chemo + hyperfractionated RT
 * PMID 12062596 (2002)

 * 92-02 (1992-95) - Prostate - long-term (AST/2 + EBRT + 2 years AST) versus short-term (AST/2 + EBRT) androgren suppression; locally advanced.
 * chapter link
 * PMID 18413638 (2008): LT-ADT better than ST-ADT, but survival difference only for GS 8-10

 * 91-16 - Bladder - Pilot Study of the Quality of Life of Bladder Cancer Patients Being Treated on the Companion Protocol RTOG-8903
 * chapter link

 * 91-15 - H&N - Phase III. Stage I-II. Chemoprevention with isotretinoin to prevent second malignant tumors.
 * chapter link
 * PMID 16595780: No benefit

 * 91-14 - CNS - High grade glioma. Quality of life and neuropsychological evaluation.
 * PMID 9211998 (1997)

 * 91-12 - Cervix - A RANDOMIZED COMPARISON OF 5FU INFUSION + BOLUS CISPLATIN AS AN ADJUNCT TO RADIATION THERAPY, VS RADIATION ALONE IN SELECTED PATIENTS WITH STAGE 1-A2,1B,IIA, CARCINOMA OF THE CERVIX FOLLOWING RADICAL HYSTERECTOMY AND NODE DISSECTION
 * PMID 10764420 (2000)

 * 91-11 - H&N - Larynx preservation: Induction Chemotherapy/XRT vs Concomitant Chemo/XRT vs XRT alone
 * chapter link
 * PMID 12525193 (2003): Chemo-RT superior over induction chemo-RT or RT alone
 * PMID 14645636 (2003): Salvage laryngectomy acceptable complication rate

 * 91-08 - H&N - Role of p105 as a predictor of outcome from prior RTOG protocols
 * PMID 7913703 (1994): Flow cytometry evaluation for p105 and DNA may be predictive

 * 91-06 - Lung - Phase II. Inoperable NSCLC. BID RT with concurrent daily oral etoposide + IV cisplatin.
 * PMID 8648357 (1996)

 * 91-05 (INT 0115) ECOG E3590 Protocol (PDF) - Lung - post-op chemo/RT vs post-op RT.
 * chapter link
 * PMID 11071672 (2000): No difference in OS or LC

 * 91-04 - CNS - Brain mets, unresected RPA class 1-2, compared 54.4 Gy BID boost vs 30 Gy in 10 fx.
 * PMID 9336134 — "A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104." Murray KJ et al. Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):571-4.

 * 91-03 Protocol - NSCLC - PFTs and serum markers evaluated after RT

 * 90-20 (closed) - Prostate - Phase II. EBRT + Etanidazole.
 * Conclusion PMID 8948352 : "Results of this trial regarding PSA response and clinical disappearance of disease are similar to historical controls and do not warrant further investigation of etanidazole as was done in this trial."

 * 90-19 (closed) - Prostate - High risk post-RP patients (ECE, SV+, SM+). RP +/- adjuvant EBRT.
 * chapter link
 * PMID 17538167 (2006): Improved PSA and clinical RFS, no impact on DM-RFS

 * 90-15 - Lung - Unresectable NSCLC. Phase I/II BID RT + concurrent chemotherapy.
 * PMID 7712445 (1995)

 * 90-12 - Esophagus - Phase II. High dose RT
 * chapter link
 * PMID 10078631 Conclusion: high dose tolerable

 * 90-05 - CNS - Radiosurgery, maximum tolerated dose, for brain mets and primary brain tumors. Established 24 Gy, 18 Gy, and 15 Gy for tumors < 2 cm, 2.1-3 cm, and 3.1-4 cm.
 * First report: PMID 8621289 (1996), Final report: PMID 10802351 (2000)

 * 90-03 - H&N - Compare Daily Hyperfractionation, Accelerated Hyperfractionation with a Split, Accelerated Fractionation with Concomitant Boost, and Standard Fractionation Radiotherapy for Squamous Cell Carcinomas of the Head and Neck
 * chapter link
 * PMID 10924966 (2000): HF or CB better than standard fractionation; split course AF comparable

 * 90-01 (1990-97) - Cervix - Pelvis+Paraaortic RT vs Pelvic RT + Chemo
 * PMID 10202164 (1999), 2002 ASTRO Plenary #1, PMID 14990643 (2004)

80-XX to 89-XX

 * 89-05 - CNS - Brain mets. RT +/- bromodeoxyuridine.
 * PMID 7673021, 1995

 * 89-03 - Bladder - T2-T4a. Bladder preservation. Randomized to +/- MCV before RT + cisplatin.
 * chapter link
 * PMID 9817278

 * 89-02 - Rectum - Local excision for distal rectal CA.
 * chapter link
 * PMID 10661337 (2000): Feasible, but high failure rate for T2/T3

 * 89-01 - NSCLC - Phase III. pN2. Induction chemo followed by 1) surgery vs 2) RT.
 * chapter link
 * PMID 12243809 (2002), PMID 18257399 (2008) - QOL

 * 88-24 - H&N - post-op concurrent chemo/RT (phase II, not randomized)
 * PMID 9128951

 * 88-23 (closed) - Liver - Phase I/II. Unresectable HCC. Induction CT/RT, followed by intra-arterial cisplatin and I-131 Antiferritin
 * Conclusion PMID 9612600 "Patients with unresectable alpha-fetoprotein-positive hepatocellular carcinoma experienced improved survival and decreased toxicity when managed with post-induction cycles of intra-arterial cisplatin as compared with intravenous doxorubicin and 5-FU. Intravenous 131I-polyclonal antiferritin did not improve survival when added to either post-induction regimen but dramatically increased hematologic toxicities."

 * 88-22 (closed) - Palliation - Prostate or Breast bone mets. Dose-escalated fractionated hemibody irradiation
 * PMID 8823257 : "The maximum tolerated dose of fractionated (2.50 Gy) HBI was found to be 17.5 Gy. The major dose limiting toxicity was hematological (thromboleukopenia). There was not a significant dose response effect on occult disease (appearance of new disease) or in the requirement for additional treatment, although certain trends were noted for the higher doses. When only patients completing assigned HBI from RTOG 82-06 and 88-22 were compared, there was no difference in the time to new disease or additional treatment in the treated field. Based on the investigative parameters of this study, single high-dose HBI was as effective as fractionated HBI."

 * 88-17 (Intergroup 0099) - H&N - Nasopharynx chemo/RT vs RT (Al-Sarraf)
 * chapter link
 * PMID 9552031: Superior survival for concurrent chemo-RT

 * 88-15 (INT 0096) - SCLC - Phase III. Standard RT 45/25 vs. AHFX 45/30 BID. Concurrent cisplatin/etoposide
 * chapter link
 * PMID 9920950 (1999): Hyperfractionated regimen better OS

 * 88-14 - Bladder - Phase II. Neoadjuvant Chemotherapy with MCV (MTX/CDDP/VBL) with Intraoperative Electron Beam Radiotherapy and Pre- and Postoperative External Beam Radiotherapy in Patients with Invasive Bladder Carcinoma
 * chapter link

 * 88-09 - H&N - Phase I/II, comparing two accelerated fractionation: Split course 1.6 Gy BID to 67.2 Gy, 2 week break after 38.4 Gy vs. 1.8 Gy + 1.5 Gy concomitant boost for last 11 fractions to 70.5 Gy
 * chapter link
 * PMID 7790243: both arms can be used successfully

 * 88-08 / ECOG 4588 - NSCLC - Unresectable Stage II-IIIB. std RT vs induction chemo/RT vs hyperfractionated RT.
 * PMID 7707407 (1995), PMID 10669675 (2000)

 * 88-06 - CNS lymphoma - Phase I/II. HIV-negative CNS lymphoma treated with CHOD x 2 -> WBRT to 41.4 Gy boosted to 59.4 Gy.
 * PMID 8636771 (1996)

 * 88-04 - NSCLC - Phase II. Unresectable. Induction/concurrent vinblastine + cisplatin.
 * PMID 1313202 (1992), SCLV mets - PMID 10386642

 * 88-02 - Bladder - Operable T2-T4a . Bladder preservation.
 * chapter link
 * PMID 8558186 (1996)

 * 87-05 - Hyperthermia - Phase I/II. Radiotherapy and Hyperthermia in Patients with Selected Measurable Superficial Tumors
 * PMID 8256760

 * 87-04 - Anal - Phase III. RT + 5-FU + Mitomycin vs RT + 5-FU
 * chapter link
 * PMID 8823332 (1996): Use of Mitomycin necessary

 * 87-03 - Hyperthermia - Phase I/II. Combined Modality Therapy with DDP and Regional Hyperthermia in Patients with Malignancies of the Pelvis and Lower Abdomen

 * 86-12 - CNS - IUdR
 * PMID 8407393 (1993), 8985039 (1996)

 * 86-10 (closed) - Prostate - Concurrent and adjuvant Zoladex + Flutamide with XRT. Bulky primary disease (>25 cc)
 * PMID 18172188 (2008)
 * Conclusion PMID 11483335 : "In patients with Gleason score 2--6 carcinoma of the prostate, a short course of androgen ablation administered before and during radiotherapy has been associated with a highly significant improvement in local control, reduction in disease progression, and overall survival."

 * 86-09 - Neutron Therapy cancer.gov link - Phase III

 * 86-08 - Rectum, Cervix, Bladder - Phase I/II. WR-2721 Administered Before Protracted Fractionated Radiotherapy in Patients with Cancer of the Rectum, Cervix, or Bladder

 * 85-31 (closed) - Prostate - N+ or cT3/pT3, Zoladex at time of radiation vs radiation alone. Excluded bulky disease (see 86-10) unless there was +LN outside of pelvis.
 * Conclusion PMID 15817329 : "In a population of patients with unfavorable prognosis carcinoma of the prostate, androgen suppression applied as an adjuvant after definitive RT was associated not only with a reduction in disease progression but in a statistically significant improvement in absolute survival. The improvement in survival appeared preferentially in patients with a Gleason score of 7-10."

 * 85-30 - H&N - Standard surgery +/- cricopharyngeal myotomy
 * chapter link
 * PMID 10488976: No benefit

 * 85-28 - CNS - solitary brain met, Phase I/II, dose escalation with hyperfractionated boost.
 * PMID 8435812 — "Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28." Epstein BE et al. Cancer. 1993 Feb 15;71(4):1362-7.
 * PMID 8330997
 * NOTE:Countered by 91-04

 * 85-27 - H&N - etanidazole + XRT
 * chapter link
 * PMID 7790241: no difference

 * 85-12 - Bladder - T2-4. Bladder preservation.
 * chapter link
 * PMID 8478228 (1993)

 * 85-06 - Bile Duct - Phase I/II. Unresected, resected but residual, or locally recurrent biliary duct cancer. Intra-op RT (14-22 Gy) followed by EBRT (45-50 Gy). 2/8 pts alive at publication w/ median follow-up 10.5 months
 * PMID 1514529 -- Intraoperative radiation therapy of extrahepatic biliary carcinoma: a report of RTOG-8506. (Wolkov HB, Am J Clin Oncol. 1992 Aug;15(4):323-7.)

 * 85-03 (INT 0034) - H&N - Post-op RT vs. post-op cisplatin/5-FU then RT
 * chapter link
 * PMID 1618662: No benefit

 * 85-02 (1985-89) - Gyn / Palliation - Phase I/II? Palliation for advanced pelvic malignancies. 3.7 Gy BID to 44.4 Gy with break after 4th and 8th fractions. Break duration randomized 2 vs 4 wks.
 * chapter link
 * PMID 8083097 (1994), PMID 7679668 (1993), PMID 2476426 (1989)

 * 85-01 - Esophagus - XRT alone vs XRT/Chemo - increased OS for T1-3 N0-1 M0 squamous cell and adenocarcinomas
 * Update: Abstract Full text — "Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group." Cooper et al. JAMA. 1999 May 5;281(17):1623-7.
 * First report: Abstract — "Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus." Herskovic et al. N Engl J Med. 1992 Jun 11;326(24):1593-8.
 * Race: Abstract: Does Race Influence Survival? — "Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01?" Streeter et al. Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1047-52.

 * 84-19 - Protocol Recurrent or persistent tumors -- Phase III Randomized Study of Interstitial Thermoradiotherapy vs Interstitial Radiotherapy Alone for Metastatic, Recurrent, or Persistent Tumors
 * PMID 8600093 (1996): No benefit as delivered

 * 84-12 / GOG 71 (1984-91) - Cervix - TREATMENT OF PATIENTS WITH SUB-OPTIMAL (BULKY) STAGE 1B CARCINOMA OF THE CERVIX. A RANDOMIZED OF RADIATION THERAPY VS RADIATION PLUS ADJUVANT EXTRAFACIAL HYSTRECTOMY
 * PMID 12798694, 2003 - Keys

 * 84-11 - H&N, Breast, Sarcoma - Phase III Randomized Comparison of Radiotherapy plus Hyperthermia vs Radiotherapy Alone in the Treatment of Patients with Head and Neck Carcinoma, Breast Cancer, or Soft Tissue Sarcoma Amenable to Potentially Curable Radiotherapy

 * 84-07 (1984-89) - Lung NSCLC - Phase I/II, concomitant boost: 45 Gy/1.8 (daily) + 18 Gy/10 fx (2-3x/week) = 63 Gy; escalate to 50.4 + 19.8 Gy = 70.2 Gy / 5.5 wks or 45 + 25.2 = 70.2 Gy / 5 wks.
 * PMID 7836079, 1993

 * 84-05 (closed) - Liver - Phase I/II dose escalation, GI liver mets, whole liver RT 1.5 Gy BID escalated to 27, 30, 33, 36 Gy (not reached).
 * Conclusion: PMID 8365932 "The study design could not credibly establish a safe dose for hepatic irradiation, however, it did succeed in determining that 33 Gy in fractions of 1.5 Gy is unsafe, carrying a substantial risk of delayed radiation injury. The absence of apparent late liver injury at the 27 Gy and 30 Gy dose levels suggests that a prior clinical trial of adjuvant hepatic irradiation in patients with resected colon cancer may have employed an insufficient radiation dose (21 Gy) to fully test the question."

 * RTOG 84-03 - Lung NSCLC / PCI - RT alone vs RT + PCI for NSCLC (non-metastatic).
 * PMID 1651304, 1991

 * 83-19 (closed) - Liver - Phase III. HCC. CT/RT Induction followed 1 month later by CT +/- 131-I-Antiferritin
 * Conclusion PMID 9612600: "Intravenous 131-I-polyclonal antiferritin did not improve survival when added to either post-induction regimen but dramatically increased hematologic toxicities."

 * 83-15 (1983-87) - CNS Lymphoma - Phase II. RT alone, 40 Gy WBRT + 20 Gy boost.
 * PMID 1572835, 1992

 * 83-14 - Anal - Phase II. RT + 5-FU + Mitomycin
 * chapter link
 * PMID 2724350 (1989): Effective

 * 83-13 (1983-1987) - H&N - hyperfractionation dose escalation: 1.2 Gy BID to 67.2 Gy, 72.0 Gy, 76.8 Gy, 81.6 Gy
 * PMID 2180866 (Preliminary): Higher LC with 72.0 and 76.8 Gy hyperfractionated, led to RTOG 90-03
 * PMID 7790242 (Long-term): No increase in late toxicity

 * 83-12 - Lung NSCLC - Phase I/II, T3-T4 NSCLC. Concomitant boost at 1.8 Gy/fx to 50.4 Gy (elective nodal). Primary tumor to 2.68 Gy/day to total of 75 Gy in 28 fx.
 * PMID 7860394 (1995)

 * 83-11 - Lung NSCLC - Phase I/II dose escalation, randomized to 1.2 Gy BID to 60.0, 64.8, 69.6 Gy, 74.4 Gy or 79.2 Gy.
 * PMID 2167952 (1990)

 * 83-03 - Bladder - Phase I/II. Dose escalation 60.0 Gy, 64.8 Gy, or 69.6 Gy. Evaluation of Twice-Daily Fractional Radiotherapy for Locally Advanced Stage B/C/D Transitional Cell and Unresectable Squamous Cell Carcinoma of the Bladder
 * chapter link
 * PMID 3058657 (1988): Good tolerance to hyperfractionation

 * 83-07 (closed) - Prostate - XRT + DES vs XRT + Megace - similar results but different toxicities
 * Conclusion PMID 7721614 : "The results of the study indicate comparable efficacy (using tumor clearance as an end point) of DES and Megestrol. Although DES appears more effective in suppressing testosterone, it is also associated with a higher incidence of drug-related toxicity."

 * 83-05 - Melanoma - dose per fraction. 4 x 8.0 Gy (32 Gy) once weekly vs 20 x 2.5 Gy (50 Gy) 5 days/week.
 * PMID 1995527 — "Fraction size in external beam radiation therapy in the treatment of melanoma." Sause WT et al. Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):429-32.

 * 83-02 (1983-89) - CNS - Phase I/II. High grade gliomas. Dose-escalation of hyperfractionated or accelerated HF RT with BCNU.
 * PMID 8608540 (1996), PMID 8380567 (1993), PMID 1451073 (1992)

 * 83-01 (closed) - Liver - Phase I/II. HCC. Induction CT+RT, followed 1 month later by 131-I-antiferritin + CT
 * Conclusion PMID 2415692: "These studies have demonstrated the toxicity and therapeutic activity of 131I antiferritin and the emerging role of radiolabelled antibody in cancer therapy."

 * 82-06 (closed) - Palliation - Bone mets. 30 Gy EBRT +/- 8 Gy hemibody irradiation
 * Conclusion PMID 1374061 : "This clinical trial demonstrates that HBI has the potential to be used to treat systemic and occult metastases, particularly if both halves of the body can be treated."

 * 81-17 - H&N - Piloted RT + chemo. Standard RT with concomitant cisplatin (100 mg/m2) q3weeks x 3 courses. Included oropharynx, nasopharynx, oral cavity.
 * chapter link
 * PMID 3802013 and PMID 2224782: Concurrent cisplatin + RT safe and effective; led to RTOG 91-11

 * 81-16 - H&N - Phase I/II. Induction cisplatin/5-FU + surgery + RT (42 patients) or surgery + sequential cisplatin/5-FU + RT (29 patients)
 * chapter link
 * PMID 1998567: No difference between induction or sequential chemo

 * 81-10 - Bladder - Phase III Photon vs Mixed Beam Preoperative Radiotherapy for Stage B/C/D Carcinoma of the Bladder
 * chapter link

 * 81-08 - Lung NSCLC - feasibility study of hyperfractionated RT
 * PMID 1650526 (1991)

 * 81-06 - Bladder - Phase III Randomized Comparison of Sandwich vs Standard Preoperative Adjuvant Radiotherapy in Stage B/C Bladder Cancer
 * chapter link

 * 81-05 - Bladder - Phase I/II Misonidazole and Radiotherapy for Inoperable Bladder Cancer
 * chapter link

 * 80-05 (1980-84) - Cervix - RT +/- misonidazole
 * link to text. Negative trial
 * PMID 3104249 (prelim, 1987), PMID 10348279 (final results, 1999)

 * 80-03 (closed) - Liver - Phase III. Liver mets. RT +/- radiosensitization with misonidazole
 * PMID 3597149: No benefit

70-XX to 79-XX

 * 79-28 (closed) - Liver - Phase I/II. 131-I-Antiferrin, Liver RT and ADR/5-FU
 * Conclusion: PMID 6275989 - "Present results suggest that further clinical studies with isotopic immunoglobulin are indicated."

 * 79-20 (1979-86) - Cervix - Pelvic only vs Pelvic + Paraaortic RT.
 * PMID 2211198 (1990), PMID 7616634 (1995)

 * 79-16 (1979-83) - CNS - Brain mets. Randomized to 30/10 vs 30 Gy/6 fx/3 wks, and +/- misonidazole
 * PMID 1993631

 * 79-15 - H&N - Misonidazole
 * chapter link
 * Hemoglobin concentration - PMID 2689395 (1989)

 * 79-13 - H&N - Hyperfractionated 1.2 Gy BID vs. standard fractionation
 * chapter link
 * PMID 3542916: No difference, worse acute toxicity

 * 79-05 (1979-82) - Gyn/Palliative - 10 Gy x 3 courses, 4-wk apart
 * chapter link
 * PMID 2442127 (1987)

 * 79-04 - H&N - Hypofractionated RT +/- Misonidazole
 * chapter link
 * PMID 2646255: No difference

 * 78-26 - Bladder - Photon Radiotherapy vs Pion Radiotherapy for Transitional Cell Carcinoma of the Urinary Bladder
 * chapter link

 * 78-21 - Bladder - Phase I/II Radiosensitization with Misonidazole plus Radiotherapy for Bladder Cancer
 * chapter link
 * PMID 7180834

 * 78-17 - Hypoxia - Phase II Study of Misonidazole plus Intraoperative Radiotherapy for Nonresectable Carcinomas

 * 78-16 - Hyperthermia - Phase I-II Hyperthermia (43.5 Degrees Centigrade) Before and After Radiation Treatment for Human Tumors

 * 78-10 (closed) - Palliation - Bone mets. Hemibody dose escalation
 * Conclusion: PMID 2423225 - "HBI achieves pain relief sooner and with less evidence of pain recurrence in the irradiated area than conventionally treated patients. The most effective and safest of the HBI doses tested were 600 rad for the upper HBI and 800 rad for the lower or mid-HBI."

 * 78-04 - Bladder - Adjuvant Radiotherapy before and after Surgery for Bladder Cancer
 * chapter link
 * PMID 3967204

 * 78-03 - H&N - Phase I/II. Induction cisplatin + bleomycin prior to RT
 * PMID 6159067: Low morbidity but not very effective

 * 78-02 - H&N - Phase II. Misonidazole pilot trial
 * chapter link
 * PMID 7333912: 67% CR rate in Stage III-IV

 * 77-08 - H&N - PI/II. Advanced patients. Induction VCR+Bleo+MTX
 * PMID 6180625: satisfactory result

 * 77-06 (closed) - Prostate - Prostate field vs. Whole pelvis + prostate boost. Stage A2-B, N0.
 * Conclusion: PMID 3058656 - "The results of the study revealed no statistically significant benefit of elective pelvic irradiation.

 * 77-05 - Bladder - Radiotherapy with Neutrons Alone or with Photons with or without Surgery for Urinary Bladder Cancer
 * chapter link
 * PMID 6375854

 * 77-03 - H&N - Phase I/II. Hyperfractionation pilot: 1.25 Gy BID and 1.5 Gy BID
 * chapter link
 * 1.2 Gy BID tolerable; 1.5 Gy BID too toxic. Led to RTOG 79-13

 * 76-19 - H&N - Registry study
 * chapter link
 * PMID 2674073: Risk of second primary cancers 15% at 5 years

 * 76-15 - H&N - Phase I-II. Neoadjuvant and concurrent chemo-RT (VBM=VCR,Bleo,MTX)
 * Too toxic

 * 76-13 - H&N - Phase I-II. Combined multidrug chemo/RT (Cytoxan,VCR,Bleo) + adjuvant chemo
 * PMID 85493: Too toxic

 * 76-12 - Bladder - Preoperative or Postoperative Radiotherapy or Radiotherapy Alone for Clinical Stage B1 or B2 or C Bladder Carcinoma
 * chapter link

 * 76-08 - Cervix - Phase III. Photons vs. photons + neutrons
 * No difference

 * 76-06 (1976-79) - CNS - Brain mets, favorable patient population (controlled primary, no extracranial mets). Rand to 30/10 vs 50/20
 * PMID 6171553

 * 76-05 (closed) - Liver - Phase I. Treatemnt of liver mets with RT

 * 75-06 (closed) - Prostate - Pelvis XRT +/- periaortic nodes
 * PMID 3494005

 * 74-02 - Bone metastases - Solitary 40.5/15 vs. 20/5; Multiple 30/10 vs. 15/5 vs. 20/5 vs. 25/5
 * PMID 6178497 (1982)

 * 74-01 / ECOG 1374 - CNS - High grade glioma. 1) 60 Gy whole brain vs 2)60 Gy + 10 Gy boost vs 3)60 Gy + BCNU vs 4)60 Gy + CCNU + DTIC
 * PMID 3281031 (1988)

 * 73-61 (1973-76) - CNS - Brain mets. Various doses: 20/5, 30/10, 40/15. Ultra-rapid: 6 Gy x 2. (RTOG 69-01 and 73-61 are grouped together.)
 * PMID 6154024, PMID 6174490, PMID 6169424

 * 73-03 (1973-79) - H&N - Pre-op 50 Gy vs Post-op 60 Gy RT.
 * chapter link
 * PMID 3449477: Post-op better

 * 73-02 - Lung NSCLC - T4 or N3 (IIIB). Palliation. Randomized to 30 Gy, 40 Gy continuous, or 40 Gy split.
 * PMID 2579938 (1985)

 * 73-01 - Lung NSCLC - Stage III. Randomized to 40 Gy split course or 40 Gy, 50 Gy, or 60 Gy continuous.
 * PMID 6998937 (1980 - patterns of tumor recurrence)

 * 71-05 - Cervix - Phase III. Stage IIB-IVA. Randomized to RT 51/30 vs. split course 25/10 + 25/10. Both followed by BT boost 30 Gy LDR
 * chapter link
 * PMID 6406397: No difference

 * 71-04 - Bladder - Phase III. Stage C or D1. Randomized to RT 60/30 vs. split course 27.5/10 + 27.5/10
 * PMID 4050737: No difference

 * 71-03 - H&N - Phase III. Nasopharynx. Randomized to RT 66/33 vs. split course 30/10 + 30/10
 * chapter link
 * PMID 6993442: No difference

 * 71-02 - H&N - Phase III. Base of tongue. Randomized to RT 66/33 vs. split course 30/10 + 30/10
 * chapter link
 * PMID 6343309: No difference

 * 71-01 - H&N - Phase III. Tonsillar fossa. Randomized to RT 66/33 vs. split course 30/10 + 30/10
 * chapter link
 * PMID 8213620: No difference

 * 70-02 - H&N - Phase III. RT +/- Carbogen
 * chapter link
 * PMID 120869: No difference

 * 70-01 - Cervix - Phase III. RT vs. Hypofractionated RT + Hyperbaric Oxygen
 * chapter link
 * PMID 7028700: No difference

Pre 70-XX

 * 69-01 (1971-73) - CNS - Brain mets. Various doses: 30/10, 30/15, 40/15, 40/20. Ultra-rapid: 10 Gy x 1. (RTOG 69-01 and 73-61 are grouped together.)
 * PMID 6154024, PMID 6174490, PMID 6169424

 * 68-01 (1968-1972) - H&N - Phase III. Stage III-IV OC, OP, SGL, HP. Randomized to RT alone vs. induction MTX followed by RT
 * chapter link
 * PMID 7410127: No benefit

title: Radiation Oncology/RTOG Trials


text:
Van Dwelling/Van Pictures

 * Van Dwelling/Van Pictures/1990 Nissan Sentra 2 door sedan
 * Van Dwelling/Van Pictures/1983 Chevy Diesel SuperVan Conversion
 * Van Dwelling/Van Pictures/Mercedes Car Conversion

title: Van Dwelling/Van Pictures


text:
General Chemistry/Periodic Table

This table is a detailed periodic table that does not fit on most computer screens. However, in print with a small font, or in landscape mode, this table can be printed onto a single normal-sized paper (A4 or 8½ x 11"). For a printable version that uses less colored ink (and works without color), see this.

Atomic masses in brackets are the most stable isotope.

title: General Chemistry/Periodic Table


text:
Talk:68000 Assembly

Is this book over PowerPC assembly or 68K assembly. The introduction would have you think that the 68K and the PPC are compatable. So, if this book wants to hold true to its title, then all the material should be removed. Otherwise the title of the book should be changed to 68K Assembly.

 * Fixed. The title is now 68000 Assembly, the PowerPC Assembly is a completely separate book, and the confusion between them in the text has now been fixed to point out that they are, in fact, completely different assembly languages. --DavidCary (talk) 14:59, 9 September 2009 (UTC)

title: Talk:68000 Assembly


text:
Bartending/Cocktails

This is an index of the recipes for various mixed alcoholic drinks, and their non-alcoholic equivalents. Cocktails of historical significance are also listed at Wikipedia.

Alphabetical list of all cocktails: A-Z glossary of cocktails

Cocktails categorized by major ingredients:
 * Cocktails with beer
 * Cocktails with bourbon
 * Cocktails with brandy
 * Cocktails with gin
 * Cocktails with rum
 * Cocktails with tequila
 * Cocktails with vodka
 * Cocktails with whiskey
 * Cocktails with wine

Other categories:
 * Cocktails with amaretto
 * Cocktails with Jägermeister
 * Cocktails with orange flavored liqueur
 * Cocktails with sake
 * Cocktail shots and shooters
 * Flaming beverages
 * Other cocktails
 * Non-alcoholic cocktails

Lista över drinkar zh:酒:鸡尾酒 Livre de cuisine/Boissons/Cocktails

title: Bartending/Cocktails


text:
Talk:Bartending/Cocktails

Edit history from List of cocktails as of 05:53, 11 Oct 2004 (UTC) :

05:21, 2004 Oct 11 Netoholic M (category) 13:32, 2004 Oct 8 Mahjongg M 13:42, 2004 Oct 6 Fanghong (Cocktails with wine) 13:37, 2004 Oct 6 Fanghong M 23:02, 2004 Sep 29 195.137.58.8 (Cocktails with vodka) 15:04, 2004 Sep 26 Hemanshu (Non-alcoholic cocktails) 15:01, 2004 Sep 26 Man vyi M (Cocktails with wine - Kir) 12:54, 2004 Sep 26 Jboy 21:57, 2004 Sep 25 192.88.124.202 (Cocktails with vodka) 17:28, 2004 Sep 24 128.40.81.141 (Added the White Lady) 21:58, 2004 Sep 20 160.39.139.127 (Cocktails with gin) 21:12, 2004 Sep 20 160.39.139.127 (Cocktails with gin) 20:58, 2004 Sep 20 160.39.139.127 (Cocktails with gin) 16:20, 2004 Sep 17 129.2.211.72 (spelling correction) 14:09, 2004 Sep 13 Radman1 M (Cocktails with vodka - Added Salmiakkikossu) 14:03, 2004 Sep 9 202.45.107.1 (ADDED jamies suicide vodka) 08:29, 2004 Sep 7 68.5.202.49 (Cocktails with sake) 03:49, 2004 Sep 7 Kaszeta M (Cocktails with beer - Added Radler) 12:12, 2004 Sep 6 80.58.3.170 (Cocktails with wine - Kalimotxo) 14:11, 2004 Aug 30 Cfailde M (Cocktails with rum - disambiguated Tom and Jerry) 13:12, 2004 Aug 30 Cfailde M (Cocktails with gin - disambig Lady Finger) 22:33, 2004 Aug 26 63.198.190.51 (Cocktails with tequila) 10:50, 2004 Aug 19 The Land 03:55, 2004 Jul 30 Alkivar (Cocktails with beer) 01:18, 2004 Jul 29 Dainamo (Cocktails with beer) 04:34, 2004 Jul 17 Casito M (Regional Lexicon to General Lexicon) 03:36, 2004 Jul 17 67.165.78.163 (Cocktails with whiskey/whisky) 03:34, 2004 Jul 17 67.165.78.163 (Cocktails with whiskey/whisky) 03:03, 2004 Jul 17 67.165.78.163 (Cocktails with vodka) 03:02, 2004 Jul 17 67.165.78.163 (Cocktails with whiskey/whisky) 03:01, 2004 Jul 17 67.165.78.163 (Cocktails with whiskey/whisky) 14:28, 2004 Jul 14 12.47.224.12 (Cocktails with wine) 17:01, 2004 Jul 12 82.82.215.68 07:04, 2004 Jul 12 64.28.54.130 (Shots/shooters) 13:01, 2004 Jul 9 169.252.4.21 (Other cocktails) 11:04, 2004 Jul 8 193.95.199.109 (Non-alcoholic cocktails) 10:37, 2004 Jul 6 Tostadora (added Poison Arrow) 08:53, 2004 Jun 28 Gadfium M (disambiguate links) 00:59, 2004 Jun 11 80.139.24.19 (Cocktails with beer) 13:26, 2004 Jun 9 69.90.55.211 (External links) 17:33, 2004 Jun 8 24.193.28.175 (External links) 16:20, 2004 May 28 217.231.203.65 01:02, 2004 May 25 GTBacchus M (=Cocktails with whiskey/whisky=) 01:00, 2004 May 25 GTBacchus M (=Shots/shooters=) 00:59, 2004 May 25 GTBacchus M (=Cocktails with whiskey/whisky= +Lynchburg lemonade) 21:37, 2004 May 22 Delirium M 20:59, 2004 May 22 Lempicka M (=Cocktails with rum= added Planter's Punch) 19:37, 2004 May 17 209.11.79.83 00:25, 2004 May 8 AlexCruise M (=Cocktails with vodka=) 00:24, 2004 May 8 AlexCruise M (=Cocktails with vodka=) 10:35, 2004 Apr 21 203.45.230.188 21:21, 2004 Apr 19 66.185.85.80 04:00, 2004 Apr 19 Fuelbottle M (=Other cocktails=) 22:56, 2004 Apr 14 195.188.152.16 22:54, 2004 Apr 14 195.188.152.16 22:53, 2004 Apr 14 195.188.152.16 14:39, 2004 Apr 14 Carruthers M (moved mimosa to wine section) 20:15, 2004 Apr 13 Carruthers M 20:13, 2004 Apr 13 Carruthers (+suburban) 16:14, 2004 Apr 13 Carruthers M (added Manhattan link to whisky section) 09:43, 2004 Apr 6 Nilmerg M (=Non-alcoholic cocktails= fix link) 23:43, 2004 Mar 28 82.41.26.198 (Added link for tequila slammer under 'shooters') 21:49, 2004 Mar 19 80.58.5.44 (just adding a link to Sangria... cheers!) 10:40, 2004 Mar 19 62.231.34.137 22:16, 2004 Mar 16 Scarequotes (Added Negroni to gin section.) 20:27, 2004 Mar 16 Deus Ex M 17:58, 2004 Mar 12 Omegium (Removed cocktail.com, since it is under construction) 20:40, 2004 Mar 6 212.235.113.23 22:15, 2004 Feb 23 Sashal M 18:13, 2004 Feb 22 66.32.130.93 (three additions) 05:49, 2004 Feb 22 Silsor M (rm self reference) 07:43, 2004 Feb 17 Sashal M (Corrected link to Rose's lime juice.) 22:10, 2004 Feb 16 Kimiko M (changed markup to use TOC) 06:07, 2004 Feb 11 Sashal 03:37, 2004 Feb 11 Amanda Rose 03:26, 2004 Feb 11 Amanda Rose M 03:55, 2004 Feb 7 Sashal 18:47, 2004 Feb 5 Jengod M (dab) 17:10, 2004 Jan 17 Robartin M (mint julep is made specifically with bourbon whiskey) 15:40, 2004 Jan 12 Jpatokal M (Kamikaze fixed) 17:44, 2004 Jan 11 Maximus Rex M (Reverted to last edit by Fab) 17:28, 2004 Jan 11 217.88.183.254 22:36, 2003 Dec 22 Fab M (-spam) 23:32, 2003 Dec 4 131.107.3.83 (removed Aviation from "Vodka" list) 23:00, 2003 Nov 13 62.155.187.73 22:59, 2003 Nov 13 62.155.187.73 12:16, 2003 Nov 11 210.86.61.23 04:36, 2003 Nov 2 Hashar M (fr: interwiki) 09:19, 2003 Oct 30 203.94.234.2 09:17, 2003 Oct 30 203.94.234.2 (Added a link to another comprehensive cocktails recipe page) 10:32, 2003 Oct 16 Lupinoid M (rm invalid carriage-return) 10:20, 2003 Oct 16 Lupinoid M (+ja:) 19:58, 2003 Sep 25 ( M (Martini cocktail) 19:53, 2003 Sep 25 ( M (Martini cocktail) 19:49, 2003 Sep 25 ( M (Martini cocktail) 19:06, 2003 Sep 25 217.88.182.245  00:05, 2003 Sep 23 Vudujava M  17:42, 2003 Sep 13 BeNude M  19:56, 2003 Aug 25 63.136.113.37  14:12, 2003 Aug 10 Bartosz (Added Rabid Dog)  22:27, 2003 Aug 9 Cjmnyc M (+caipirinha)  22:24, 2003 Aug 9 Cjmnyc (+vodka martini; +cosmopolitan; +gibson)  21:43, 2003 Aug 9 Cjmnyc (+Aviation)  17:42, 2003 Aug 4 198.152.12.68 (boston cooler)  16:24, 2003 Jul 23 Zoicon5 (added a personal favorite)  22:31, 2003 Jul 6 Stevewestinlondon M (manhatten placed in boubon catogory)  10:48, 2003 Jun 18 Schneelocke (Add a number of non-alcoholic cocktails.)  12:38, 2003 Jun 14 213.157.26.224 (Longdrink)  00:16, 2003 Jun 3 209.99.108.2  00:05, 2003 May 30 209.99.108.2  10:36, 2003 May 23 Ap M  01:48, 2003 May 23 Michael Voytinsky M (Added 'bleeding brain' - need to do an entry on that as well)  19:27, 2003 May 15 Ihcoyc M (+ Black Velvet) 19:25, 2003 May 15 Ihcoyc M (rem. ext. space) 14:55, 2003 May 13 Ihcoyc (+ Cocktails with beer) 19:25, 2003 May 4 Ap M 00:01, 2003 May 4 65.94.51.84 00:58, 2003 Apr 26 144.134.185.123 00:29, 2003 Mar 15 Notheruser M (bourbon disambig) 17:03, 2003 Mar 2 Docu M (Upd. Links) 01:53, 2003 Jan 27 Tzaquiel M (Added cement mixer and fixed vodka gimlet link) 19:30, 2003 Jan 26 Tzaquiel M 19:22, 2003 Jan 26 Tzaquiel (Formatting, added section for bourbon) 05:35, 2003 Jan 18 4.46.52.220 14:34, 2003 Jan 1 Deb (adding a couple) 18:16, 2002 Dec 23 162.83.141.253 18:15, 2002 Dec 23 162.83.141.253 18:13, 2002 Dec 23 162.83.141.253 18:12, 2002 Dec 23 162.83.141.253 18:10, 2002 Dec 23 162.83.141.253 18:07, 2002 Dec 23 162.83.141.253 06:55, 2002 Dec 23 24.61.43.104 M 11:06, 2002 Dec 14 Sam Francis (** Three Rivers) 12:53, 2002 Nov 15 Ap M 13:41, 2002 Oct 31 212.69.216.34 13:38, 2002 Oct 31 212.69.216.34 13:36, 2002 Oct 31 212.69.216.34 (Added Kamikaze) 19:38, 2002 Oct 28 Dachshund M (Rossini cocktail) 21:11, 2002 Oct 5 206.15.46.129 M (+rum cocktail) 21:08, 2002 Oct 5 195.149.37.6 (Geisha, seems to be one of the better known sake cocktails) 15:52, 2002 Oct 5 194.117.133.84 15:51, 2002 Oct 5 194.117.133.84 16:49, 2002 Oct 1 David depaoli 16:41, 2002 Oct 1 David depaoli 07:38, 2002 Sep 25 Andre Engels M 16:19, 2002 Sep 24 Andre Engels M  22:45, 2002 Sep 11 Dachshund M (separated Cuba Libre and Rum and Coke) 10:29, 2002 Aug 4 Eclecticology 06:39, 2002 Jul 23 Ap M 07:18, 2002 Jul 22 8.163 (added lots of cocktails) 21:36, 2002 May 23 10.58 15:51, 2002 Feb 25 Carey Evans M (oops, Sangrita was already here) 03:44, 2002 Feb 25 Carey Evans ( + sangrita link) 14:19, 2002 Feb 16 Carey Evans (with tequila, articles to come) 05:05, 2002 Feb 16 Szopen (Uboot shooter) 02:12, 2002 Feb 4 WojPob M 22:53, 2002 Jan 28 Conversion script M (Automated conversion) 23:37, 2002 Jan 2 144.132.75.xxx (added a couple of shooters) 21:23, 2002 Jan 2 The Cunctator M 21:22, 2002 Jan 2 The Cunctator M  19:55, 2002 Jan 2 Hagedis 19:28, 2002 Jan 2 Dmerrill 22:24, 2002 Jan 1 RobertL30 (Mojito) 22:23, 2002 Jan 1 RobertL30 22:23, 2002 Jan 1 RobertL30 22:22, 2002 Jan 1 RobertL30 M (rum and cola) 20:55, 2002 Jan 1 The Cunctator M 01:46, 2002 Jan 1 The Epopt M  01:44, 2002 Jan 1 24.15.135.xxx (Alphabatized within sections; added mixes) 01:38, 2002 Jan 1 The Epopt M 01:09, 2002 Jan 1 The Epopt (Tom Collins and Old Fashioned) 21:36, 2001 Dec 31 Hagedis (unlink zombie) 21:21, 2001 Dec 31 Sodium M 20:38, 2001 Dec 31 The Cunctator (*Some commentary on cocktails.) 20:17, 2001 Dec 31 Sodium 19:28, 2001 Dec 31 209.75.42.xxx M 19:24, 2001 Dec 31 209.75.42.xxx M (Mimosa, etc.) 18:59, 2001 Dec 30 Magnus Manske M (+Virgin Pina Colada) 18:50, 2001 Dec 30 The Epopt (Mother Superior) 23:20, 2001 Dec 29 Hagedis (expanding definition (again)) 23:18, 2001 Dec 29 24.82.9.xxx 23:18, 2001 Dec 29 24.82.9.xxx 23:18, 2001 Dec 29 24.82.9.xxx 23:04, 2001 Dec 29 Ap (daikiri -> daiquiri) 23:00, 2001 Dec 29 AxelBoldt 22:00, 2001 Dec 29 Hagedis (bloody mary) 21:55, 2001 Dec 29 Hagedis (expand definition to encompass non alcoholic cocktails) 20:35, 2001 Dec 29 Ap (added some non-alcoholic cocktails) 20:20, 2001 Dec 29 Ap (expanded a bit on the history of the cocktail) 16:33, 2001 Dec 29 Hagedis M 16:30, 2001 Dec 29 Hagedis (definition and links) 16:03, 2001 Dec 29 Ap (added some rum based cocktails) 23:06, 2001 Dec 19 Dan (spelling edit) 16:55, 2001 Dec 18 WojPob 16:53, 2001 Dec 18 WojPob

Pruning
As this is ostensibly a bartender's guide, wouldn't it make sense to remove recipes for things like Eggnog that would never be produced by a bartender? Also, it seems reasonable to separate cocktails and shooters onto separate pages. Thoughts?

For that matter, is anyone actively reading this at all?

 * I am. Though there is not much going on here it seems. Similar to the WikiProject Cocktails project. I would encourage anyone reading this to join the Project over there so we can get some cross-wiki discussion going on. I think there are several ways we can help each other out.

 * As to the eggnog question, the same type of question has come up over there. What I am proposing at Wikipedia is to make "mixed drinks", not cocktails, be the top-level of the hirearchy. True cocktails would be the largest section thereunder, but there would also be places for things like eggnog, spritzers, beer mixes, and other things that aren't technically cocktails. I'm not sure how things are organized here, but you might consider something similar to that if it makes sense in your wikiverse. :-) --Willscrlt 13:04, 9 December 2006 (UTC)

Fleshing Out Cocktail List
Over the next little while, I'm going to flesh out the cocktails list by creating all the non-existant pages linked to from this main page, and filling in recipes as described by Google, the almighty. These should be fairly correct, but I'm sure people will want to then make alterations for accuracy/variations. Hope this helps. Lor 21:37, 5 September 2005 (UTC)

Indik
Wikipedia is discussing deleting a recipe for a cocktail purportedly named "Indik". See w:Wikipedia:Articles for deletion/Indik. If any editors wish to have the recipe transwikied to here, please say so in that discussion. Uncle G 00:32, 19 September 2005 (UTC)

Field research?
Barmeister and drinkmixer and iDrink and friends are all giving different results. I'm going to do some field research; I've added a Bartending:region|(region) template in case anyone does some field research and polls at least say 5 bartenders from your area, preferably in different establishments. It's shown to the right. It may be wise to regionalize the bartending wikibook, or find another way to denote that things come from various regions.

I'm especially interested in non-alcoholic cocktails, being myself one who dislikes alcohol's flavor and effects. I don't get off on being slightly out of it, or plastered to the wall, or vomiting in someone's face; I like my brain operating at peak efficiency at all times. This is my only strong interest in this wikibook; plus it will help eat some of my free time on weekends, social engineering my way into bars.

I'm a newcomer - is this still active?
I'm slightly newish to Wikipedia and Wikibooks and I'm just wondering if these projects are still active? Italydiplo (talk) 06:00, 8 July 2008 (UTC)

title: Talk:Bartending/Cocktails


text:
Category:Cocktails

This category contains cocktail recipes.

de:Kategorie:Cocktails ka:კატეგორია:კოქტეილები

title: Category:Cocktails


text:
Windows XP/Windows-key Shortcuts

Are you a user who finds reaching for the mouse an annoying action? If so, then consider keeping your fingers on the keyboard to accomplish the same objectives by using the keyboard shortcuts listed below.

 * Windows Key + E
 * Opens the Explorer window.

 * Windows Key + D
 * Brings the desktop to the foreground. If you repeat the keyboard combination, it returns the desktop to the background and the open windows will return to their original state.

 * Windows Key + F
 * Displays the Search Result window.

 * Windows Key + L
 * Locks your Windows computer (Windows XP or higher)

 * Windows Key + M
 * Minimizes all open windows to display the Desktop.

 * Windows Key + R
 * Displays the Run command. (try that and type in OSK - just in case you have no keyboard)

 * Windows Key + F1
 * Displays the Help and Support Centre window.

 * Windows Key + Pause/Break
 * Displays the Systems Properties dialog box.

 * Windows Key + Tab
 * Cycles through the buttons on the Task Bar. To activate the selected button on the Task Bar, press the Enter key.

 * Alt + Tab
 * Toggles or switches between open windows.

 * Alt + F4
 * Closes the active window.

title: Windows XP/Windows-key Shortcuts


text: User:Mike

title: User:Mike


text:
Talk:Statistics/Distributions/Binomial

I edited and moved around a bunch of stuff, hopefully clarifying the writing in the process. The original author seemed to confuse statistics (e.g., "how many people in the US have green eyes") with probability (e.g., "if I grab thirty random people off of the street what is the probability that 3 of them will have green eyes"). I also removed some of the "informal" language and rephrased it to be a little more technical. --Llywelyn 09:43, 11 Oct 2004 (UTC)

title: Talk:Statistics/Distributions/Binomial


text:
Statistics/Probability

Probability is connected with some unpredictability. We know what outcomes may occur, but not exactly which one. The set of possible outcomes plays a basic role. We call it the sample space and indicate it by S. Elements of S are called outcomes. In rolling a dice the sample space is S = {1,2,3,4,5,6}. Not only do we speak of the outcomes, but also about events, sets of outcomes (or subsets of the sample space). E.g. in rolling a dice we can ask whether the outcome was an even number, which means asking after the event "even" = E = {2,4,6}. In simple situations with a finite number of outcomes, we assign to each outcome s (∈ S) its probability (of occurrence) p(s) (written with a small p), a number between 0 and 1. It is a quite simple function, called the probability function, with the only further property that the total of all the probabilities sum up to 1. Also for events A do we speak of their probability P(A) (written with a capital P), which is simply the total of the probabilities of the outcomes in A. For a fair dice p(s) = 1/6 for each outcome s and P("even") = P(E) = 1/6+1/6+1/6 = 1/2.

The general concept of probability for non-finite sample spaces is a little more complex, although it rests on the same ideas.

Why have probability in a statistics textbook?
Very little in mathematics is truly self contained. Many branches of mathematics touch and interact with one another, and the fields of probability and statistics are no different. A basic understanding of probability is vital in grasping basic statistics, and probability is largely abstract without statistics to determine the "real world" probabilities.

This section is not meant to give a comprehensive lecture in probability, but rather simply touch on the basics that are needed for this class, covering the basics of Bayesian Analysis for those students who are looking for something a little more interesting. This knowledge will be invaluable in attempting to understand the mathematics involved in various Distributions that come later.

Set notion
A set is a collection of objects. We usually use capital letters to denote sets, e.g. A is the set of females in this room.

 * The members of a set A are called the elements of A, e.g. Patricia is an element of A (Patricia ∈ A); Patrick is not an element of A (Patrick ∉ A).
 * The universal set, U, is the set of all objects under consideration, e.g., U is the set of all people in this room.
 * The null set or empty set, ∅, has no elements, e.g., the set of males above 2.8m tall in this room is an empty set.
 * The complement Ac of a set A is the set of elements in U outside A, i.e. x ∈ Ac iff x ∉ A.
 * Let A and B be 2 sets. A is a subset of B if each element of A is also an element of B. Write A ⊂ B, e.g. the set of females wearing metal frame glasses in this room ⊂ the set of females wearing glasses in this room ⊂ the set of females in this room.

• The intersection A ∩ B of two sets A and B is the set of the common elements. I.e. x ∈ A ∩ B iff x ∈ A and x ∈ B.

• The union A ∪ B of two sets A and B is the set of all elements from A or B. I.e. x ∈ A ∪ B iff x ∈ A or x ∈ B.

Venn diagrams and notation
A Venn diagram visually models defined events. Each event is expressed with a circle. Events that have outcomes in common will overlap with what is known as the intersection of the events.

Negation
Negation is a way of saying "not A", hence saying that the complement of A has occurred. Note: The complement of an event A can be expressed as A' or Ac For example: "What is the probability that a six-sided die will not land on a one?" (five out of six, or p = 0.833)

P[ X' ] = 1 - P[ X ] $$ Or, more colloquially, "the probability of 'not X' together with the probability of 'X' equals one or 100%."

Relative frequency describes the number of successes over the total number of outcomes. For example if a coin is flipped and out of 50 flips 29 are heads then the relative frequency is $$\frac{29}{50}$$ The Union of two events is when you want to know Event A OR Event B. This is different from "And." "And" is the intersection, whereas "OR" is the union of the events (both events put together). In the above example of events you will notice that... Event A is a STAR and a DIAMOND. Event B is a TRIANGLE and a PENTAGON and a STAR (A ∩ B) = (A and B) = A intersect B is only the STAR But (A ∪ B) = (A or B) = A Union B is EVERYTHING. The TRIANGLE, PENTAGON, STAR, and DIAMOND Notice that both event A and Event B have the STAR in common. However, when you list the Union of the events you only list the STAR one time! Event A = STAR, DIAMOND   EVENT B = TRIANGLE, PENTAGON, STAR When you combine them together you get (STAR + DIAMOND) + (TRIANGLE + PENTAGON + STAR) BUT WAIT!!! STAR is listed two times, so one will need to SUBTRACT the extra STAR from the list. You should notice that it is the INTERSECTION that is listed TWICE, so you have to subtract the duplicate intersection.

Conjunction
Formula for the Union of Events: P(A ∪ B) = P(A) + P(B) - P(A ∩ B)

Example: Let P(A) = 0.3 and P(B) = 0.2 and P(A ∩ B) = 0.15. Find P(A ∪ B). P(A ∪ B) = (0.3) + (0.2) - (0.15) = 0.35

Example: Let P(A) = 0.3 and P(B) = 0.2 and P(A ∩ B) = 0. Find P(A ∪ B). Note: Since the intersection of the events is the null set, then you know the events are DISJOINT or MUTUALLY EXCLUSIVE. P(A ∪ B) = (0.3) + (0.2) - (0) = 0.5

Law of total probability
The law of total probability is[1] a theorem that, in its discrete case, states if {\displaystyle \left\{{B_{n}:n=1,2,3,\ldots }\right\}}\left\{{B_{n}:n=1,2,3,\ldots }\right\} is a finite or countably infinite partition of a sample space (in other words, a set of pairwise disjoint events whose union is the entire sample space) and each event {\displaystyle B_{n}}B_{n} is measurable, then for any event {\displaystyle A}A of the same probability space:

{\displaystyle P(A)=\sum _{n}P(A\cap B_{n})}{\displaystyle P(A)=\sum _{n}P(A\cap B_{n})} or, alternatively,[1]

{\displaystyle P(A)=\sum _{n}P(A\mid B_{n})P(B_{n}),}{\displaystyle P(A)=\sum _{n}P(A\mid B_{n})P(B_{n}),} where, for any {\displaystyle n}n for which {\displaystyle P(B_{n})=0}{\displaystyle P(B_{n})=0} these terms are simply omitted from the summation, because {\displaystyle P(A\mid B_{n})}{\displaystyle P(A\mid B_{n})} is finite.

Conditional Probability
What is the probability of one event given that another event occurs? For example, what is the probability of a mouse finding the end of the maze, given that it finds the room before the end of the maze?

This is represented as:

P[A | B] $$

or "the probability of A given B."

$$P(A | B) = \frac{P(A\cap B)}{P(B)}$$

If A and B are independent of one another, such as with coin tosses or child births, then:

P[A | B] = P[ A ] $$

Thus, "what is the probability that the next child a family bears will be a boy, given that the last child is a boy."

This can also be stacked where the probability of A with several "givens."

P[A | B_1, B_2, B_3 ] $$

or "the probability of A given that B1, B2, and B3 are true?"

-->

title: Statistics/Probability


text:
Cookbook:Caribbean cuisines

| North America

Countries

 * Cuisine of the Bahamas
 * Cuisine of Cuba
 * Cuisine of The Dominican Republic
 * Cuisine of Jamaica
 * Cuisine of Puerto Rico
 * Cuisine of Trinidad and Tobago
 * Cuisine of Antigua
 * Cuisine of Haiti

Recipes

 * Jamaican Jerk Chicken
 * Stamp & Go
 * Saltfish & Ackee
 * Callaloo

ka:კულინარული წიგნი:კარიბული სამზარეულო

title: Cookbook:Caribbean cuisines


text:
Talk:Windows XP/Windows-key Shortcuts

Help the A+ certification book. --Cyberman 00:49, 7 Feb 2005 (UTC)

Hope someone can help ith the layout and structure - then we geeks can fill in all the top tips. ..
 * Hmm... seems like a start, but it looks more like Windows tips-and-tricks than know how. In time, perhaps. >_> --MikeRS 02:22, 17 Dec 2004 (UTC)

Interesting, but, PCI Express ISN'T 1-2 years down the road, it's here now, with PCI-X slots showing up on every current board and shipping with the new Dell 'puters for months now. I tell ya, 16x graphics with a 3GHz p4 and 4GB of 533MHz DDR is pretty darn SWEEEEET! --Weaponofmassinstruction

I agree with the first comment, this document is a structural mess. There's also a lot of plain vague or overly specific stuff that would need to be improved. And to either change the name to Windows Know-How or generalise the content.

How about changing this to Using Windows/Tips and Tricks and building a book out of Using Windows and these things into just a chapter (after much cleaning of course). I am not volunteering, I still have two books I myself am working on at the moment, but I think that the Using Linux, Using Windows, Using Mac OS X and any other operating system books would be neat rather than one big mess referring to computers as the operating system. 70.24.120.242 04:05, 7 Feb 2005 (UTC)

Perhaps make a Using Windows 2000, XP and 98 editions. Nmontague 08:07, 7 Feb 2005 (UTC)

I'll second user 70.24.120.242 suggestion.--64.36.31.178 01:15, 17 August 2005 (UTC)

Windows and Linux are merging ? That's far from true. Yoric 19:24, 15 June 2006 (UTC)

I've started organizing things a bit and adding content. This book is still a mess. Don't hesitate to improve itYoric 21:54, 15 June 2006 (UTC)

title: Talk:Windows XP/Windows-key Shortcuts


text:
Cookbook:Edible dormouse

These were considered a great delicacy by the Romans and were raised in special earthenware jars. The animals have also apparently been an important food source in Slovenia and are still eaten today. Two recipes have survived from Roman times:

 * Glazed with honey and rolled in poppy seeds (Petronius)
 * Stuffed them with a mixture of pork mince, dormouse meat trimmings, pepper, nuts, asafoetida and garum and then roasting or boiling them (Apicius 8.9.1)

title: Cookbook:Edible dormouse


text:
User:Eequor~enwikibooks/standard.css

div.editsection {  clear: left; }

div#article {  border-top: 3px groove #330099; border-left: 3px groove #330099; border-bottom: 2px groove #997fcc; padding-top: 3px; padding-left: 8px; padding-bottom: 1em; }

h1, h2, h3, h4, h5, h6 { position: relative; clear: left; left: -8px; padding-left: 8px; overflow: hidden; border-bottom: 2px groove; }

h1 {  color: #000000; border-left-color: #000000; border-bottom-color: #7f7f7f; }

h2 {  color: #110033; border-left-color: #110033; border-bottom-color: #887f99; max-width: 88%; }

h3 {  color: #220066; border-left-color: #220066; border-bottom-color: #907fb2; max-width: 77%; }

h4 {  color: #330099; border-left-color: #330099; border-bottom-color: #997fcc; max-width: 68%; }

h5 {  color: #4400cc; border-left-color: #4400cc; border-bottom-color: #a17fe5; max-width: 60%; }

h6 {  color: #5500ff; border-left-color: #5500ff; border-bottom-color: #aa7fff; max-width: 53%; }

hr.sep {  color: #330099 !important; background-color: #997fcc !important; height: 2px !important; }

img {  max-width: 512px; }

pre {  border: 1px dashed blue; padding: 8px; margin: 1em; overflow: auto; display: table; clear: left; }

pre.raw {  border: none !important; padding: 0 !important; margin: auto !important; display: normal !important; clear: none !important; }

td.top {  border-bottom: none !important; }

td.bottom {  border-top: none !important; }

{  display: none; }
 * 1) siteNotice, #editpage-copywarn

{  border-right: none !important; }
 * 1) quickbar

title: User:Eequor~enwikibooks/standard.css


text:
Cookbook:Hedgehog

The old Romani way to cook a hedgehog is to roll it in clay and bake it in the embers of a bonfire. When ready, the clay is broken open and the spines come away still embedded in it.

title: Cookbook:Hedgehog


text:
Cookbook:Guinea Pig

Guinea pigs are a traditional food source in the Andes. Meals incorporating guinea pig are particularly associated with ceremonial occasions. Although the meat was for a time falling out of favour there has been a resurgence in its consumption. The most traditional Peruvian manner of cooking guinea pig involves building a stone pit and lining it with llama dung and firewood and then burying guinea pig carcasses in the coals once the fire has built up heat.

title: Cookbook:Guinea Pig


text:
Cookbook:Chuu Chee Fish

| Thai Cuisine

Chu Chee Fish is whole fish in kaeng chuu chee curry sauce with lime leaves. This very tasty distinctly Thai fish dish is great as one of the main courses of a Thai banquet. It is also good on its own with rice.

Ingredients

 * 650 g whole bream or similar fish
 * 1 metric cup vegetable oil (reserve 1 tablespoon for stir-frying curry paste)
 * 1 teaspoon of kaeng chu chee curry paste
 * 6 dried Kaffir lime leaves
 * 1 metric cup coconut milk
 * 1 tablespoon (warning: perhaps the metric 20 mL one) fish sauce
 * 1 teaspoon sugar
 * Fresh cilantro
 * 1 fresh red chile pepper

Procedure

 * 1) In a wok or large frypan, over high heat, fry fish using most of the vegetable oil, until golden on one side. It will take about 5 minutes.
 * 2) Lower heat and, using tongs, gently turn fish over.
 * 3) Turn up heat again and cook until golden. Using tongs again, lift fish gently onto a serving plate.
 * 4) In the wok, gently stir-fry the curry-paste and lime leaves in remaining tablespoon of oil.
 * 5) Add coconut milk and fish sauce. Simmer for about 5 minutes.
 * 6) Add sugar and simmer for another 5 minutes.
 * 7) Taste to see if extra coconut milk, fish sauce, or sugar is required.
 * 8) Pour sauce over fish and garnish with cilantro and chopped chili peppers.

Warnings

 * Always wash your hands after handling chili peppers. Be especially careful not to touch your eyes, your kids, or pets.

title: Cookbook:Chuu Chee Fish


text:
User talk:195.157.146.246

Hello there! Welcome to Wikibooks! We've noticed that you've been making some great additions to the Cookbook and we really appreciate it. Why not create an account and stay awhile? Wikibooks can use as many quality members as possible. If you ever need editing help visit how to edit a page and experiment at the sandbox. If you need pointers on how we title pages visit Naming conventions. If you have any other questions about the project then check out Help or add a question to the staff lounge. Hope to see you around for a long time to come! Gentgeen 15:18, 11 Oct 2004 (UTC)

title: User talk:195.157.146.246


text:
Cookbook:White Bread

 * Bread

Procedure

 * 1) Put half of the water into a container, then add yeast and either sugar or honey.
 * 2) Take another container and put in 2 pounds (1 kg) of flour. Form a crater in the middle into which you can pour the water with the yeast. Add a pinch of salt. Knead it and keep adding water until the dough has a good thick consistency.
 * 3) Place the dough on a surface and let it stand for about 1 hour. Knead again to let the air out and knead it into the shape of a bread. Let it stand for another 45 minutes.
 * 4) Bake in an oven at 375°F (200°C) for 50–60 minutes or until the internal temperature is about 200°F (95°C).
 * 5) Now you have a nice, tasty loaf of bread.

Notes, tips, and variations

 * If your bread seems crumbly or not sufficiently soft and bouncy, try using high gluten flour. You can get special bread-making flour which is higher in gluten than normal flour.

title: Cookbook:White Bread


text:
Cookbook:Fried Chicken

Fried chicken has a dual origin in the rural American South. The Scots had a tradition of shallow cooking chicken in fat (not quite pan frying), unlike their English counterparts who baked or boiled chicken. Later, as African slaves were introduced to households as cooks, seasonings and spices were added that are absent in traditional Scottish cuisine, improving the flavor and they brought the concept of deep fat frying. Since slaves were often allowed to keep only chickens, frying chicken as a special occasion spread through the African American community. After slavery, poor rural southern blacks continued the tradition since chickens were often the only animals they could afford to raise. Since fried chicken could keep for several days, it travelled well, and also gained favor during segregation when blacks normally could not find places to eat and had to carry their own food. Southern whites also continued the tradition of frying chicken. Therefore, fried chicken continued to dominate as "Sunday dinner" or on other special occasions.

Ingredients

 * Dry ground seasonings as desired (e.g. pepper, paprika, onion powder, garlic powder, etc.)
 * 1 fryer chicken, cut up (see notes below)
 * 1 quart buttermilk
 * ½ cup salt
 * Flour
 * A quantity of oil suitable for the desired cooking method (see notes below)

Brining

 * 1) Combine all seasonings in desired quantities to make a spice rub.
 * 2) Pour the buttermilk into a bowl and dissolve in the salt.
 * 3) Piece by piece, roll the chicken around in the spice rub.
 * 4) Submerge each chicken piece in the buttermilk.
 * 5) Cover the bowl of buttermilk and chicken and refrigerate. You can get by with as few as two hours if you are in a hurry, but the flavor will suffer. You can also park it overnight, but in this case you should reduce the salt to ⅓ cup.
 * 6) Shortly before you want to cook the chicken, remove it from the buttermilk and drain. Roll it around in flour so that it is well covered in flour. Shake off the excess flour.

Deep frying
The safest cooking method is deep frying.

 * 1) Immerse chicken in 360°F oil. Cooking according to the specified time for each chicken part:
 * 2) * Breasts: 10 minutes
 * 3) * Drumsticks: 12 minutes
 * 4) * Thighs: 13–14 minutes
 * 5) * Wings: 10 minutes
 * 6) Drain the chicken on a wire rack over a sheet pan.

Pan frying
The most traditional cooking method is pan frying in a cast iron skillet. Care must be taken to avoid spilling and splattering.

 * 1) Heat enough oil (or shortening) to come 3–4 mm up the side of the pan to 325°F.
 * 2) Carefully place chicken in pan, skin side down. Cook until brown (10–12 minutes). Turn over and cook other side. Doing this will require some careful placement in the pan so as to cook the slow-cooking meat (such as thighs) more intensely than the fast-cooking meat (such as wings and breasts).
 * 3) Drain the chicken on a wire rack over a sheet pan.

Pressure frying
Pressure frying gives excellent results, but special equipment is needed. A typical pressure cooker is not suitable for cooking with large quantities of oil; a pressure fryer must be used. Follow the manufacturer's instructions carefully.

 * 1) Put the chicken pieces into hot oil (larger pieces first) and fry about 3 minutes until very light brown. Then put on the lid and lock it.
 * 2) Cook at a pressure of 5–6 pounds for about 7 minutes.
 * 3) Drain the chicken on a wire rack over a sheet pan.

Notes, tips, and variations

 * The key to this recipe is the buttermilk brine, which seasons the chicken with a salty tanginess inside. Combined with a suitably zingy spice rub, this works out beautifully.
 * This recipe is death to oil, so it's one you might want to save until you're thinking about changing your fryer oil anyway.
 * As with all respectable fried chicken recipes, this recipe may be even better 24 hours after you cook it, when the chicken has been refrigerated.
 * If you can get a pre-cut chicken, this is ultimately easier. Alternatively, if you have a real preference for drumsticks, thighs, breasts, or some other part, feel free to buy just those. The quantities in the ingredient list, however, reflect two breasts, two thighs, and two drumsticks. Don't waste the other parts on fried chicken; save them for chicken soup! But if you like fried chicken wings, increase the quantities a bit.
 * If you are kosher, lactose intolerant, not fond of buttermilk, or feeling experimental, feel free to play around with other possible brines here. If you use a less viscous liquid than buttermilk, however, you may need to use an egg wash to make sure that the flour sticks to the chicken in sufficient quantity.
 * Wings can also be saved, along with other leftover bits of carcass, to make chicken soup.
 * Personal preference chooses which spice to use as a base. A paprika-based rub works very well for this recipe, but others will work just fine. Cumin or curry powder would also both be good choices. You can use rosemary powder and green bell pepper powder in order to give a more mediterranean taste to fried chicken.

title: Cookbook:Fried Chicken